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ABSTRACT
Non-invasive drug delivery systems for therapeutic drugs are gaining prominence.
One such system, the nasal delivery system, shows good prospect for effective delivery
of some drugs, however, it is yet to be well established for others. The preparation of a
reformulated drug and studying its in vitro characteristics is a crucial step in the process
o f adapting the new drug for nasal delivery systems. The purpose of this research is to
study the effect of electrostatic layer by layer assembly of polyelectrolytes on
PROMAXX® insulin microparticles and to study the chemical, physical and
corresponding release properties of the resulting formulations. PROMAXX® insulin
microparticles o f recombinant human insulin prepared and provided by Epic Therapeutics
Inc®. During reformulation the temperature, pH, salt concentration and excepient
concentrations were controlled to achieve maximum yield of final product and minimize
raw material consumption. In vitro release studies were performed to study the release
properties of various formulations prepared by electrostatic layer-by-layer assembly and
compared with a standard insulin formulation. A key finding involved that the control
release o f insulin can be achieved by suitable selection of first polycation layer, and the
consequent polyelectrolyte layers can be used to fine-tune the release. In addition,
polyelectrolyte requirements were established for production o f grams of final product.
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To retard the permeability of thin films prepared with electrostatic layer-by-layer
assembly, lipid bilayers were incorporated in layer by layer assembly. Study of diffusion
properties of the composite multilayer films demonstrated that outermost lipid layer on
hollow polyelectrolyte microcapsules acts as an effective diffusion barrier for FITCdextran (MW 4300), which is comparable to insulin (MW 5800), and hence an important
development towards imparting stealth and sustained release properties to low molecular
weight drugs.
Hydrophobic drugs pose a problem for entrapment in polymeric matrices due to
their poor solubility in aqueous media. In an effort to the study cores other than protein
and drug microcrystals for nasal drug delivery, calcium carbonate microparticles
incorporating

phospholipids

and

hydrophobic

molecules

were

prepared

and

characterized. The hydrophobic molecules were co-entrapped with anionic phospholipids
in the calcium carbonate matrix with a near homogenous distribution of the molecules in
the matrix, with loading up to 4 % (w/w) of calcium carbonate. Further, the anionic
phospholipids influence the crystal morphology o f calcium carbonate resulting in a
decrease in release o f hydrophobic molecules due to decreased rate of re-crystallization.
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CHAPTER 1

INTRODUCTION

Over the last ten decades healthcare has improved considerably throughout the
world, improving life expectancy of humankind. Advances in science and technology
have provided amenities for a comfortable living, which coupled with a sedentary
lifestyle have led to an increasing number of people who suffer from diabetes.
Pharmaceutical companies are trying to cope with increased demand for new drugs and
better delivery systems for existing drugs.
Major players in the drug market are characterized by two main traits, namely the
discovery o f new drugs, or reformulation of existing drugs. The drug delivery market is
intensely competitive and survival of a company depends on the ability to innovate and
obtain patent protections for new developments and enhanced products. The cost of
developing a new drug from discovery to marketing is close to a billion dollars.
Therefore, emphasis on improvement of delivery methods is inevitable for the industry
due to economic reasons. Lately, more attention is being given to particulate delivery
systems with known size distributions to achieve better predictable pharmacodynamics
and pharmacokinetics. An increasing number of patents are being filed for novel
microencapsulation techniques themselves. This work is an effort to achieve that

1
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competitive edge through product enhancement and innovation through the study of
fundamental processes involving surface chemistry changes at nano and microscale.
1.1

Microencapsulation

Microencapsulation is not a new concept and has been in use since the early 20th
century. Numerous methods exist for encapsulation of many active agents, with wideranging applications including but not limited to food, consumer products, cosmetics, and
pharmaceuticals. Microencapsulation in most instances aims to protect the encapsulated
material and/or to enhance its stability. Many microencapsulation schemes involve the
entrapment of simple molecules and usually entail harsh processing conditions such as
high temperatures, and use of non-aqueous solvents and surfactants.
1.1.1 Microcapsules and Microparticles
A general summary of microencapsulation methods is presented in Table 1.1.

Table 1.1. Classification of microencapsulation methods [1].
Process

Coating material

Suspended medium

Interfacial polymerization

W ater-soluble and insoluble monomers

Aqueous/organic solvent

Complex coacervation

W ater-soluble polyelectrolyte

W ater

Coacervation

Hydrophobic polymers

Organic solvent

Thermal denaturatlon

Proteins

Organic

Salting-out

W ater-soluble polymer

W ater

Solvent evaporation

Hydrophilic or hydrophobic polymers

Organic or water

Hot melt

Hydrophilic or hydrophobic polymers

Aqueous/organic solvent
Organic solvents

Solvent removal

Hydrophilic or hydrophobic polymers

Spray-drying

Hydrophilic or hydrophobic polymers

Air, nitrogen

P h a se separation

Hydrophilic or hydrophobic polymers

Aqueous/organic

The microencapsulation methods described in Table 1.1 produce particles
generally characterized as microcapsules or microspheres. Microcapsules can be defined
as a continuous envelope enclosing a well defined core and microspheres as solid
particles with a homogenous or a heterogeneous core. The alternate architectures of
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microcapsules and microsphere produced through the microencapsulation methods listed
in Table 1.1 are shown in .

Gaseous core

\v

V,

/

Spherical

Sol k) com

Liquid core

;d jfi
Sphericat

Irregular

/

\

Pure or dissolved

\

Suspension

\ w / VWv
Irregular

Matrix

Multi-

Emulsion

Emulstonsuspension

compartmental
(a)
Gasacxis

Solid

Liquid

mm
Spherical

Spherical

Irregular

Irregular

Soiid solution

Pure or dissolved
drug

Suspension

Emulsion

Emutsionsuspenskm

(b)

Figure 1.1. Various configurations of, (a) microcapsules and (b) microspheres [1].

Microcapsules consist of different solid, liquid or gaseous active material
entrapped in a solid shell (a). Microspheres on the other hand have a solid matrix with
active material dispersed as gas bubbles, liquid droplets, emulsions, or solid particles
dispersed in the microsphere matrix. In this work two types of particles will be discussed
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widely microcapsules of emulsion-suspension type with a semi-solid core such as insulin,
and microspheres with solid solution type in which organic micelles occur discreetly in a
solid calcium carbonate core ().
More recently, many new drugs coming in the market are large biomolecules such
as proteins, peptides, DNA and oligonucleotides. The use of harsh treatment with such
active agents could potentially result in degradation of the active agent, subsequently
causing loss of bioactivity.

1.2 Importance of Size in
Microencapsulation
A wide range o f sizes is permissible for particle size in drug delivery depending
on the drug delivery method employed and the nature of active formualation. Table 1.2
summarizes the typical size ranges of pharmaceutically relavent particle sizes and their
nomenclature.

Table 1.2. Particle dimension estimates in drug delivery [1].

Particle Size frm)
0.001-0.5

Examples
Proteins, polymers, oligonucleotides, DNA, micelles,
microemulsions, colloidal suspensions

0.5-10
10-50
50-150
150-1,000
1,000-3,400

Suspensions, fine em ulsions, micronized drugs
C oarse emulsions, flocculated suspensions
Fine powders
C oarse powders
Granules

Currently, micronized drugs and microemulsions with narrow particle size ranges
are becoming favored over larger particulate and/or polydisperse systems in both
industrial and academic research. Small particles with a narrow size distribution have
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more predictable release profiles and increased bioavailability. The micronized drug
delivery with particles in the 0.5-10 pm range also show promise for nasal and pulmonary
delivery o f drugs [1].
1.3 Objectives and Novel Aspects
This work represents an advancement in a particulate drug delivery system with
the emphasis on peptide delivery using layer-by-layer (LbL) electrostatic self-assembly
and entrapment o f hydrophobic molecules in an inorganic matrix. This work advances
both particle-based drug delivery and the LbL technique itself. Further, it demonstrates
for the first time the electrostatic LbL assembly of nanofilm coatings in the presence of
high concentration of inert and semi-interacting polymer- poly(etheleneglycol).
This work demonstrates the use of economical but milder methods like the
electrostatic LbL assembly, use of an aqueous medium, phospholipids, and biologically
safer minerals such as calcium carbonate for preparing microparticles with reliably
controlled particle size distribution.
This dissertation consists of two parts, the surface modification of insulin
microparticles PROMAXX®, and the synthesis of calcium carbonate microparticles.
Specific aims and the design of experiments to achieve the objectives will be thoroughly
treated in the following discussion.
Hypothesis I
The assembly of LbL multilayers on insulin microparticles can be used to achieve
a sustained release of drug from the microparticle, impart proteolytic resistance, achieve
microparticle stabilization by preventing aggregation, stabilization of insulin tertiary
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structure through complex formation with polyelectrolytes and achieve an outermost
biocompatible coating to minimize immune response.
The work with insulin microparticles involved the surface modification of insulin
microparticles, as achieved through the use of LbL assembly. LbL assembly was chosen
because LbL assembly has significant advantages over other methods as it can be
employed in an aqueous media to deposit nanometer-thick ultrathin films with a wide
choice of materials. The conditions of LbL assembly can be achieved under mild
conditions over a wide range of temperatures.
To achieve the objectives above, said a number of aspects related to LbL
assembly need to be investigated. The first step involves choice of materials to perform
LbL assembly, followed by determining suitable temperature, assembly buffers, pH of
assembly, and centrifuge speed. Choice of materials was limited to biopolymers such as
polyaminoacids, polysaccharides, polyamides, phospholipids, and naturally occurring
peptides in either modified or unmodified form. However some experiments needed to be
performed with synthetic polyelectrolytes to establish the feasibility, and to compare
assembly results with biopolymers. This choice of biological polymers could offer better
biocompatibility compared with synthetic polymers. To establish the assembly conditions
and materials the first step involves the study and characterization of LbL assembly on
flat substrates, and on microparticles. Such a study would enable the characterization of
the effects o f different material and concentration on the release of insulin microparticles.
A simple mathematical model accounting for the release properties of different
polyelectrolyte layers, the number and order of layers would be impractical because of
variable interactions of protein-polyelectrolyte complexes. Such interactions depend on
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the functional groups of polyelectrolyte with the functional groups on the insulin
molecule, and the protein-polyelectrolyte complex can be reversible or irreversible. The
temperature and pH of assembly and consequent release studies also affect the drug
release from the microparticle. Therefore, analysis of experimental data has been used to
optimize the LbL process, establishing various parameters required for scaleup.
In this work, to scaleup the process for production of grams of final product (pilot
plant scale), the concentrations of polyelectrolytes, pH, temperature, centrifuge, assembly
medium and number of process steps need to be established and standardized for unit
weight o f insulin microparticles. These parameters need to be established by
experimentation. This physical and chemical characterization of microparticles prepared
with different polyelectrolytes, at different assembly conditions, and the consequent
release properties are expected to provide an insight into the most suitable
polyelectrolytes for in vivo testing.
Controlled experimental conditions have been used in this work, and the
experimental data generated have been used to optimize the final process scaleup, thus
establishing concentrations o f polyelectrolytes and the resulting surface and release
properties o f the drug microparticles.
Hypothesis II
Phospholipid-polyelectrolyte composite films can effectively modulate diffusion
properties of molecules smaller than MW 10,000.
As an advancement o f the work on insulin drug formulation, the use of
phospholipids in combination with polyelectrolytes can effectively modulate the
diffusion properties o f LbL nanofilms.
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Such a scheme could minimize the number of process steps for nanofilms acting
as a simple diffusion barrier [2], in addition to providing a biocompatible outermost
coating. However, before it’s in insulin formulation, the optimization of suitable
phospholipids compositions, and study of the multilayer-phospholipid-polyelectrolyte
thin film properties is the fundamental step. Assembly of single phospholipid layer on
polyelectrolyte multilayers has been demonstrated by Moya et al. [3]; however,
multilayer polyelectrolyte/phospholipid assemblies have not been demonstrated. To study
these properties, qualitative and quantitative techniques are required to establish
phospholipids compositions and corresponding LbL film properties. In addition the
optimized material composition and assembly conditions can be effectively used to
design and test the diffusion properties of such thin films using a model compound
similar to insulin. Thus, the refined technique could effectively be employed in
modulating the diffusion properties of insulin.
The second objective is to develop a particulate drug delivery system stems from
the need to develop suitable carriers for hydrophobic drugs. Most nasal delivery systems
are based on polymeric microparticles, and face a major drawback due to poor systemic
clearance of inert polymeric materials. Moreover, suitable dispersion mediums for
polymer-based microparticles involve liquids, which consequently involve significant
handling costs, and custom delivery devices. Mineral particulate systems for drug
delivery are a recent development and well suited for delivery of drugs with existing
nasal delivery devices. Calcium carbonate, apatite, and hydroxyapatite are three mineral
particulate delivery systems gaining prominence because of their biocompatible nature.
Among these calcium carbonate microparticles show promise due to their biodegradation
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rates. Adsorption of drug on surface of microparticles and delivery in vivo has been
shown to be effective for hydrophilic drugs. However, delivery of hydrophobic drugs
using calcium carbonate needs to be developed.
Hypothesis III
Hydrophobic molecules can be entrapped in calcium carbonate matrix.
This work involves the development of one such system and establishes the proof
of concept for entrapment of hydrophobic molecules in the calcium carbonate matrix.
Calcium carbonate microparticles incorporating phospholipids in the matrix and
consequently the co-entrapment of hydrophobic molecules are demonstrated. The
characterization of the microparticles using various analytical techniques, such as
thermogravimetric analysis, SEM and XRD is described. Establishing proof of concept
for entrapment o f hydrophobic molecules was achieved using a model hydrophobic
fluorescent dye.
A system employing the use of phospholipids for entrapment of a species in
calcium carbonate matrix is flexible and can in principle be employed to entrap not only
hydrophobic drugs but also hydrophilic and peptide drugs. Large drug molecules such as
proteins exhibit marked surface active property in that they partition or preferentially
adsorb on surfaces at an interface; thus it is possible to entrap such molecules using the
proposed scheme.

1.4 Organization of Chapters
This dissertation has been organized in chapters so that Chapters 3, 4, and 5 are
self contained. Some degree of redundancy has been retained to make these chapters
more readable as a contiguous piece work. Chapter 2 covers the background and theory
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of the material presented in Chapters 3, 4, and 5 as well as the principles behind the
instrumentation and computation involved. Chapter 6 summarizes the entire work and
provides recommendations for future work. Chapter 3 describes applicability of an
established technique - the electrostatic LbL assembly to enhance a pharmaceutical
product PROMAXX®. Chapter 4 describes enhancement of the LbL technique by use of
phospholipids. Chapter 5 describes the use of phospholipids to develop a novel technique
to entrap small hydrophobic materials in an inorganic and relatively inert calcium
carbonate matrix.
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CHAPTER 2

BACKGROUND AND THEORY

2.1 Introduction
In this chapter the literature concerning the insulin formulations, the LbL
technique, and inorganic/organic matrices is reviewed with respect to drug delivery.
Relevant instrumentation and theory used are presented to better understand the multiple
but succinct references to the same in the following three chapters.

2.2 Market Outlook
Pharmaceutical companies market drugs based on less-than-perfect delivery
systems or formulations, with their prime concern being limited to the safety and efficacy
o f the drug. Moreover, alternate development of drug delivery platforms and
formulations is inhibited by patent protections. To overcome these drawbacks more and
more pharmaceutical companies are partnering with drug delivery companies to codevelop marketable products. During the term of patent protection the parent company is
guaranteed artificially inflated revenue for brand-name drugs, and patent expiration
results in rapidly declining sales due to a host of generic drug manufacturers selling at a
fraction o f the price. Clinicians and patients may prefer reformulated brand-name drugs,
possibly due to increased value or improved product, and the reformulation may in turn

11
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lead to patent extension. Patent expiry also creates a window for competing firms to
improve drug formulations. Selecting a drug candidate for reformulation is governed by
the market value it generates. Figure 2.1 shows the attractiveness of reformulation for a
general drug[4].

r

ural
Oral Tablet
lai
Capsule 1
per day

Oral Tablet Capsule >1
per day
Aerosol
Nasal
Transdermal
Injectable R elease Depot
Subcutaneous injection
Intramascular injection

Hierarchy of
Reformulation

IV injection

Figure 2.1. Hierarchy o f reformulation [4].

2.3 Insulin Reformulations
2.3.1 Diabetes. Insulin and the
Pharmaceutical Industry
Diabetes, a chronic metabolic disorder, continues to be a global epidemic,
affecting more than 170 million people (WHO) globally and increasing at an alarming
rate. Type I diabetes results from inability of the body to produce insulin. This form of
diabetes is treated with insulin injections. During the eventual course of type II diabetes
(due to insulin resistance) insulin injections need to be administered to control the
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progress of the disease [5]. Thus, currently the most viable form of treatment for diabetes
for over four decades is injectable insulin. Insulin formulations, both slow-acting and
fast-acting, are widely in use. Insulin formulations are usually injected subcutaneously,
although more recently nasal, oral and transdermal delivery techniques are being
developed. However, these variants have had limited success due to various problems
such as dosage, bioavailability, and problems with prolonged use. Two popular injectable
insulin formulations o f insulin are Humulin®(Eli Lilly) and Glucophage®(Bristol-Myers
Squibb) which generated a combined $1.5 billion in sales worldwide in 1997 alone and
went off-patent in 2000 [6]. Many more drugs will go off-patent in 2005-2008, leading to
a host o f generic drug manufacturers fighting for a market share. Thus, market pressures
for discovery of new drugs or reformulation of old drugs play an important role in
determining the major players in the drug market [4].
Insulin was discovered in 1920s [7], and its method of administration has changed
little since then. The purity and quality of the final product have, however, improved
greatly with the advent o f recombinant DNA technology. Control of blood glucose levels
is the primary goal of insulin administration. Most commercial formulations achieve fast
release ~30 min-2 hr to prolonged ~ 1 day of therapeutic levels of insulin. The fast-acting
products/formulations target glucose levels immediately following a meal, and the longacting formulation targets the basal glucose level. Depending on the individual,
physicians prescribe a combination of both fast and slow formulations to achieve optimal
glycemic control and minimize the number of injections required. Although techniques
for delivering peptide drugs have evolved over the period of time the principal
components of the formulation remain the same, namely zinc, protamine and insulin,
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which are commonly used in most formulations. Insulin is an attractive and widely
researched drug; numerous publications and patents exist on its formulations.
2.3.2 Phvsiochemical Properties of
Insulin
Human insulin is a 51 amino acid peptide with molecular weight of 5700 and
isoelectric point ranging from 5.3-5.4. However, the isoelectric point of insulin varies
depending on conjugation, self-association, and modifications in amino acid sequence, or
isoforms. Various sources suggest that the value of isoelectric point of insulin can be in
the broad range from 5.2-5.9. The human insulin molecule consists of two peptide chains
(A-21 amino acids and B-30 amino acids) linked by two disulfide bonds. The primary
structure o f human insulin is shown in Figure 2.2.

A-chain
cow

R-NH’

■NH-R

Figure 2.2. Primary structure of human insulin. The shaded regions
are involved in self association [8].

The shaded regions show insulin self-association sites implicated in the formation
o f dimers or hexamers. Insulin usually assembles to dimers at acid and neutral pH; in the
presence o f zinc it forms hexamers [8]. It is slightly soluble in water and practically
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insoluble in alcohol, chloroform or ether. Because of its amphoteric nature it forms
soluble salts with weak acids and alkalis.
2.3.3 Design of Insulin Drug
Reformulation
Proteins are macromolecules and differ from conventional small molecule drugs
in that they are fragile systems with a complex architecture, and changes in the local
environment of the protein can cause severe changes in the structure and function of the
protein-drug, rendering it ineffective for treatment. The biological activity of the protein
is retained only when the integrity of their structure is maintained. Administration of
native protein alone does not achieve desired results because of rapid degradation
processes that occur in biological systems due to proteolytic activity and rapid uptake and
elimination. Therefore, it becomes imperative to design controls into the dosage form to
achieve predictable and well-defined pharmacokinetics. Particulate delivery systems are
more attractive to native enzyme because of enhanced protein and peptide stability,
reduced protein degradation, increased chemical and biological stability, and increased
bioavailability.

The particulation of drugs can be achieved by spraying and drying

techniques, use o f solvent mixtures, and homogenizing [9]. During particulation,
additives are added to the protein, and careful choice of materials reduces adverse effects

[ 10, 11].
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2.3.4 Current Insulin Drug
Reformulations
Insulin formulations and their variations can be broadly classified based on their
solubility in vivo as fast-acting or slow-acting formulations. The excepients primarily act
by conjugating/complexing with the insulin molecules in ways that enable either rapid
release (phenolic compounds), or slow-release (protamine, zinc, pegylation), of insulin
molecule from the complex. In addition to excepients, some formulations also regulate
pH of formulation as a means to crystallize/solubulize insulin and thus achieving the
desired release rate. Although different formulations contain variable concentrations of
excepients, the general constituents of the formulations are summarized in Figure 2.3.
Alternatively, insulin delivery platforms can be categorized by method of administration
as
(a) Oral/Gastrointestinal.
(b) Nasal/Mucosal.
(c) Subcutaneous/Musculoskeletal.
(d) Transdermal and other intelligent drug delivery systems.
Each of these systems is discussed in greater detail, highlighting the current state
o f research and the most promising avenues.
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Figure 2.3. Overview of Insulin Formulations.
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2.3.4.1 Oral delivery
From the reformulation hierarchy in Figure 2.1 it can be inferred the oral delivery
of insulin is the most attractive. The first attempt to formulate insulin for oral delivery
was by Oppenheim et al. [12] who prepared insulin formulation composed of particles in
the ~200 nanometer range without polymers, where the insulin was cross-linked using
glutaraldehyde. Damge et al. [13] loaded insulin into poly(alkyl cyanoacrylate) (PACA)
nanocapsules by interfacial polymerization technique in which a mixture of insulin,
isobutyl cyanoacrylate (IBCA), Mygliol® were added to an aqueous solution of
poloxamer 188. This procedure resulted in interfacial anionic polymerization and
formation o f nanoparticles -220 nm in size. The encapsulation efficiency was 55% and
the suspension was used without any further purification for in vivo tests. Michel et al.
[14] also prepared poly(isobutyl cyanoacrylate) (PIBCA) nanospheres by the
conventional emulsion polymerization technique [15]. The particles had a mean size of
150 nm. The insulin microspheres lacked protection against proteolytic enzymes when
suspended in water but were resistant to proteolytic action when dispersed in Mygliol®.
Therefore, in the particles prepared with the emulsion polymerization technique,
hydrophilic peptides tend to diffuse out to the surface of the particles which impedes the
protection of the peptide.
Although partial adsorbtion in gastrointestinal tract was speculated for
glutaraldehyde cross-linked insulin preparations, in vivo tests by Oppenheim et al. [12]
were ineffective because glutaraldehyde denatures the insulin and causes loss of
bioactivity. Moreover, the nanoparticles were predictably degraded by proteolytic
enzymes o f the gastric tract. Although, this formulation achieved a 15-20% reduction of
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glucose level in mice, which is nonetheless marginal for a commercially viable product.
In the work of Damge et al. [13], a single 100 IU/Kg administration of insulin-loaded
IBCA nanospheres resulted in reduction of glycemia by 65% in normal dogs with a
glucose overload after 3 days of oral administration. Reduction reached 72% after nine
days and 48% after 15 days. The glycemia returned to normal levels 21 days after
administration. Damge et al. [13] claimed that this impressive prolonged effect was
caused by altered biodistribution after oral administration of insulin-loaded nanoparticles.
They also claimed that if sufficient number of intact nanocapsules were absorbed,
nanocapsules would be localized in liver and spleen due to rapid phagocytosis. However,
the purification and preservation of insulin-loaded IBCA nanocapsules poses a significant
problem and is consequently poorly adapted for clinical use. To overcome this problem
PIBCA based nanospheres were prepared by Michel et al. [14]. The PIBCA based
formulation was effective after subcutaneous injection but induced no biological effect
after oral administration.
The most promising work on oral delivery systems was done by Morishita et al.
[16-18] who investigated pH-sensitive particles that would dissolve in various segments
o f digestive tract, in particular the jejunum or the ileum, where protease activities are
lower. Morishita et al. incorporated insulin with or without protease inhibitor, which was
dissolved in a small amount of HC1 (0.1 N). Ethanol and methacrylic acid copolymer
(type A, Eudragit® L I00 soluble at pH >6, or type B, Eudragit® S I00 soluble at pH >7
Rohm, Darmstadt, Germany) were added with stirring. This solution was emulsified into
liquid paraffin, phase separated with gelatin solution (0.5% w/w), and the particles
isolated. The isolated particles were coated with Eudragit® L I00 to avoid dissolution of
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the drug that was adsorbed on the surface of the particle. The total encapsulation
efficiency of insulin was 78%. Good protection against pepsin was achieved; protection
against trypsin and a-chemotrypsin was achieved with protease inhibitors. In vivo tests
indicated that Eudragit® L microspheres had enhanced biological activity in fasting wistar
rats (16-20 hr fasting).
The primary advantage of oral administration is the availability of the widest
array of materials for formulation compared with all other routes of delivery;
biocompatibility is limited to “edible substances”. The disadvantage of current
approaches to oral delivery is the extremely high doses of insulin required, for even a low
therapeutic effect compared with parenteral doses. Although the work looks promising in
rodents and dogs, it is yet to be well tested in human subjects. Overall, the oral delivery
formulations are still in the natal stages.
2.3.4.2 Nasal delivery
Evolution o f new materials has stimulated interest in alternate drug delivery
systems other than oral and injectable routes, and nasal drug delivery is an emerging
field. Nasal dosage forms consist of preparations containing dispersed or dissolved drugs
which can be either squeezed or sprayed into the nose, or applied topically as a gel
(vitamin B i2) [19, 20]. The drugs target the nasal mucosa where they deposit and are
absorbed. The nasal mucosa and epithelium primarily act as a lipophilic transport barrier,
and transport across the membrane is related to the water partition coefficient [21].
Strategies to optimize the use o f mucoadhesives for nasal delivery of insulin include (a)
preparing the formulations as micro- or nanospheres, (b) incorporation of absorption
enhancers and (c) combination of different polymers [22], The formulation design should
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also consider factors such as pH, ionic strength, surface active agents, viscosity, and drug
concentration [23], Enhancers are used in nasal formulations to improve drug absorption
across the nasal membrane. The most evaluated compounds as enhancers are
surfactants(laureth-9), bile salts (glyco-taurocholate, deoxycholate), chelators (EDTA,
citric acid), fatty acid salts (oleic, caprylic, capric, and lauric), phospholipids (L-alysophosphatidylcholine
taurodihydrofusidate,

(DDPC),

STDHF),

didecanoyl-PC,

glycyrrhetinic

acid

fusidates

derivatives

(sodium

(carbenoxolone,

glycyrrhizinate), cyclodextrins (a-, p-, y-cyclodextrins), hydroxypropyl-P-cyclodextrin
and dimethyl-p-cyclodextrin (DMPCD), randomly methylated P-cyclodextrin (RAMEB),
chitosan, and particulate carriers (microcrystalline cellulose, starch microspheres, and
liposomes). Some o f these compounds are also used in fast-acting formulations of insulin
[9]Controlled studies in humans using phospholipid DDPC as an insulin enhancer
have shown that nasal mucosal physiology was unaffected after intranasal administration,
but that insulin bioavailability was low, despite intranasal doses about 20 times higher
than subcutaneous doses [24]. Cyclodextrans are another class of compounds that show
great promise in nasal drug delivery. They interact with polar/amphoteric molecules and
also adsorb with specific lipids in biological membranes thus acting both as a carrier, and
enhancer for hydrophobic drugs. In vivo studies by Merkus et al. [25] in rats have
demonstrated that the addition of 5% a-CD to a nasal preparation o f insulin resulted in an
absolute bioavailability of approximately 30%; on the contrary, p- and y-CDs did not
affect insulin absorption. However, DMPCD gave rise to a large increase in insulin
absorption, with a bioavailability of 100%. Contrasting results were obtained in
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experiments with rabbits and human volunteers in which no absorption-enhancing effect
of CDs for insulin was observed, with a bioavailability of approximately 3-5% [1, 25].
Thus, the effectiveness of CDs depends on both the drug and the animal being tested.
Another prospective mucoadhesive formulation is chitosan, a positively charged high
molecular weight polymer. For chitosan-based formulations Dyer et al. [22] showed that
the most effective formulation for absorption is a chitosan powder delivery system, found
to be better than chitosan nanoparticles and chitosan solution formulations, respectively.
Callens and Remon reported that nasal administration of insulin formulated with drumdried waxy maize starch (DDWM) or maltodextrins and Carbopol 974P, had the highest
absolute bioavailability (14.4% for a mixture consisting of DDWM/Carbopol 974P
90/10) [26]. However use o f the formulation over a week in sheep showed reduced
bioavailability due to high viscosity of the mucoadhesive formulation [27].
Thus, the bioavailability of the administered drug is a major problem in the nasal
delivery o f insulin formulation. However, development of pulmonary insulin delivery
systems by commercial vendors is reaching critical and near market stages (Table 2.1).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

23

Table 2.1. Commercial development of pulmonary insulin systems [28].
Pulm onary Insulin Delivery System s u n d er D evelopm ent
D o s a g e F o rm
Solution

P ow der

C om pany

D e v e lo p m e n t S ta g e

AERx iDMS

Novo Nordisk, A radigm

A erodose

A erogen

Exubera

Pfizer, Aventis, N ektar

ProMaxx
AIR

Epic T h erap e u tics
Eli Lilly, Alkerm es

Spiros

Eli Lilly, Dura
P harm aceuticals

T ech n o sp h ere
Insulin S ystem

M annKind C orporation

P hase III clinical trial in
progress
P hase II clinical trial
com p leted ;
d e v e lo p m e n t h a lte d in
January 2003
P hase III clinical trial
c o m p le te d ; lo n g -term
safety stu d ie s o n g o in g ;
m ark etin g au th o rizatio n
application filed w ith
E uropean M edicine
Evaluation A gency in
March 2004; n e w d ru g
application filed w ith FDA
in 2005
Predinical stu d ies
P hase II clinical trial in
p rogress
D iscontinued a fter m e rg e r
b e tw e e n Dura
P harm aceuticals a n d Elan
Pharm aceuticals
Late P h ase II clinical trial
o n g o in g ; P h ase III clinical
trial in itiated in E urope

T ra d e N a m e

The bioavailability of commercial variants is in the range of 13-30%, slightly
higher than reported in research papers. Many enhancers used in the formulations for
nasal delivery are known to be biocompatible, and adverse reactions are limited
compared with intra-venous, intra-muscular, subcutaneous administration.
2.3.4.3 Subcutaneous/musculo
skeletal injection
This is the most widely used and established form of insulin administration.
Insulin formulations, depending on action, have common names and they have
established pharmacokinetic characteristics. These formulations fall in one of the broad
types based on duration of action as illustrated in Table 2.2.
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Table 2.2. Injectable insulin formulations [29].
PHARMACOKINETIC CHARACTERISTICS OF INSULIN
FORMULATIONS (TIME IN HOURS)
Type of Insulin

Onset

Peak

Duration

Slow-acting
Ultralente
Glargine

3-5
1-2

10-16
NA

18-24
24

Intermediate-acting
NPH
Lente

1-2
2-4

6-10
6-12

12-20
12-20

0.5-1
immediate

2-4
0.5-2

4-8
3-4

Short-acting
Regular
Lispro/aspart

Most individuals are prescribed a combination of two or more types of insulin for
optimal glycemia control. The pharmacokinetic profiles of individual insulin products
however, differ significantly [30]. The ultralente insulin formulations are slow-acting and
typically consist of zinc cross-linked hexameric insulin with or without protamine.
Insulin can be co-crystallized with zinc atoms to obtain numerous types of stable
crystals with longer time actions than soluble or amorphous, uncrystallized insulin. The
fish protein protamine has been used as insulin complexing agent to prolong the time
action o f insulin. Insulin glargine, insulin lispro, and insulin aspart are insulin analogues
which have modified amino acids and hence complex with zinc and protamine
differently. The NPH insulin is a protamine insulin complex and is intermediate acting.
The fast-acting analogues are usually co-crystallized with zinc and phenolic molecules,
and diffusion o f the phenolic molecule away from site of injection causes the insulin-zinc
crystal to break apart yielding monomers and hence the instantaneous action. Individual
manufacturers add various stabilizing additives during the formulation including albumin,
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sugars, polyols, chelating agents and inorganic salts- to confer stability in solution,
frozen and dried states as required.
Polymeric drug delivery has been studied for the past 30 years but few
commercial products have come to market. It is gaining importance because of recent
advances in polymeric materials and advantages offered by polymeric micro and
nanoparticles for delivery o f peptides. Polymeric materials are attractive for drug delivery
because they afford protection to peptide drugs, prolong release, and have controllable
biodegradeability. Commonly used materials for encapsulation of proteins are poly(llactic acid) (PLLA) and its copolymers with d-lactic acid or glycolic acid, which provide
a wide range o f degradation periods from weeks to years [31]. Most researchers use
solvent evaporation or a modification thereof to prepare microparticles for controlled
release [32, 33]. Emulsion, extrusion and spraying techniques can cause protein damage
because they involve use o f one or more of the following- organic solvents, elevated
temperature, vigorous agitation and detergents. Controlled phase separation and use of
aqueous biphase mixtures have also been employed to achieve micro- and nanoparticles.
Pfizer® in collaboration with Nektar® and Aventis® has developed a formulation
based on pegylated insulin for nasal and possible IV delivery and recently launched their
product Exubera™. However, it is not yet widely available.
Subcutaneous injection for diabetic treatment is currently the most effective
control for both Type I diabetes and eventually Type II diabetes. For this method of
administration, only FDA approved polymeric materials can be used in the formulation,
which limits the formulation composition because few polymers have been approved for
such use.
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2.3.4.4 Transdermal and other
intelligent drug delivery
systems
Minimally invasive insulin pumps are primarily used to treat the basal glycemia,
and some are programmable to release drug at specified periods of time. Insulin is
delivered transdermally using either a pressure activated, or an ionotropic, or an
ultrasonically modulated device.
Pulsatile systems involving insulin in an ethylene-vinyl acetate copolymer
(EVAc) matrix loaded with magnetic beads have been used to control the release of
insulin in vivo in rats by application of an oscillating magnetic field. The release rate is
dependent on the magnitude of the magnetic field and rigidity of the matrix. Similar
results were observed with alginate-protein matrices [34-40].
An ultrasonically controlled polymeric delivery system in which release rates of
substances can be repeatedly modulated at will, from a position external to the delivery
system were tested by Kost et al.[41]. Both bioerodible and nonerodible polymers were
used as drug carrier matrices. The bioerodible polymers evaluated were polyglycolide,
polylactide, poly(bis(p-carboxyphenoxy) alkane anhydrides and their copolymers with
sebacic acid. The releasing agents were p-nitroaniline, p-aminohippurate, bovine serum
albumin, and insulin. Non-bioerodable system consisting of EVAc-insulin was also
tested. In vitro and in vivo experiments in rats indicate feasibility of such a system. The
release was modulated by the ultrasonic frequency, intensity and duration. Instantaneous
release o f encapsulated material over two minutes was achieved upon application of
ultrasound [41]. Over 40 years, numerous clinical reports have been published
concerning phonophoresis [42], This technique is based on the basic principle that the
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drug to be transdermally transferred is placed topically, followed by application of
ultrasound. However, this method is not yet well established for protein drugs.
Competitive binding of glycosylated insulin to glucose and a saccharide binding
protein such as Concavlin A as a release mechanism for regulated insulin delivery were
first proposed by Brownlee and Cerami [43]. In vivo experiments in diabetic dogs show
promising results.
Another such smart system involves a saccharide sensitive gel that swells in the
presence of glucose. The gel consists of a covalently cross-linked polymer network of Nisopropylacrylamide in which the lectin and Con A are immobilized [44]. Other such
smart systems involving intelligent glucose responsive chemistries have been
demonstrated in vitro, but promising in vivo results are unavailable.
It would be fascinating and exciting to demonstrate the efficacy and long-term
stability o f smart chemistries in vivo. Fouling and lack of biocompatibility could be a
potential problem in such systems after a prolonged period of time. However, smart
systems currently available are underdeveloped for induction into the market. Glucose
pumps are, to the best o f my knowledge, the only commercially available devices for
insulin delivery that have a minimally invasive approach. Popular vendors of glucose
pumps include Animas Corp, Medtronic MiniMed Inc, Disetronic Medical Systems, Inc,
and Deltec Cosmo.
Discussion: The nasal/aerosol-based delivery of insulin would be better than
other methods o f administration and this modality may become practically possible in the
near future, considering current research levels in major firms. Time-release rates for the
insulin formulations by themselves cannot be judged as good or bad because both short-
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and long-acting formulations may be necessary based on patient requirements. However,
prolonged oral formulation of IBCA nanocapsules is most attractive in terms of control of
basal glycemia because prolonged bioavailability of insulin for a single dose have not
been achieved by systemic injection or other non-invasive methods.
The nasal/aerosol system has some drawbacks in its current form in terms of
bioavailability of the drug after administration. However, it is theoretically possible to
achieve quick-acting formulations because the rate of drug uptake in the lungs is
exceeded only by intravenous injection. Oral delivery is nearly impractical for fast-acting
formulations unless a very low molecular weight insulin analogue is discovered which is
extremely resistant to proteolytic activity. Intravenous and subcutaneous drug delivery
are painful, and patient compliance is not always good. It is particularly stressful for
children.
Design Criteria for Coatings: As LbL-based insulin microparticles are primarily
targeted for in vivo delivery, it is of paramount importance that all components must be
completely biocompatible and produce no adverse reactions in diabetics. This project
involves the development o f long-acting insulin formulation, so it is important to have a
tunable release o f the drug with prolonged bioavailability. The outermost LbL layer
should be designed to impart proteolytic resistance to the insulin microparticle. The
coating should impart physical and chemical stability to the encapsulated insulin. Finally
the procedure developed must be scalable and optimized with respect to concentrations of
prospective polyelectrolytes to minimize the use of the same. Repeatability and
consistency o f product and method are essential for the final product.
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During the surface modification using LbL assembly, low temperatures should be
maintained to prevent protein denaturation and/or complexation. Extremely low pH
values (<4.0) should be avoided because they lead to increased solubility of
PROMAXX® microparticles (insulin-zinc) that were used in this work. Phosphate salts
and/or compounds containing phosphate groups should be avoided because phosphate
moiety has a tendency to bind with zinc-complexed insulin, leading to reduced solubility
and marked changes of pharmacokinetic activity of the final formulation. It is also
important to avoid any other contaminants and non-sterile media in samples to be
dissolution tested.

2.4 Phospholipids Retard Diffusion of
LbL Thin Films
Electrostatic LbL has earned significant focus over the last decade because of the
simplicity o f the technique. It has evolved from the study of the fundamental science of
LbL thin films to applications in real world product development. One practical area of
interest is drug delivery. The basic scheme of the LbL assembly is shown in Figure 2.4.
Thin films of opposite charge are deposited on a solid substrate by electrostatic assembly
in an alternate manner to achieve sequential growth of thickness with each deposited
layer. LbL assembly can be used to deposit thin films from a wide range of materials
from metal complexes and polymers to proteins and nanoparticles (Figure 2.4 (top)), or to
prepare hollow multilayer capsules (Figure 2.4 (bottom))[A5-Al],
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Figure 2.4. LbL schemes for polymers, proteins, nanoparticles
(top). Preparation of hollow polyelectrolyte capsules (bottom).

The versatility of the process allows the use of LbL technique on both template
particles and flat surfaces, irrespective of the size of the object. It can be used to design
hollow capsules or thin films, and the choice of materials is extensive and limited by the
charge on the polymer, nanoparticle or protein. Thorough reviews of the technique have
been elaborated elsewhere [45, 48-52]. More recently, drug delivery applications were
elaborated by the deposition of multilayer thin films on the drug microparticles [53-56],
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The primary focus of these works is the design of multilayer thin film coatings on drug
crystals and the tuning of release properties by increasing the number of polyelectrolyte
bilayers on the drug microcrystal. The universality of the idea implies no fundamental
restriction on the choice of materials and the possibility of designing ultrathin ordered
films in the range of 5-500 nm, with the precision of greater than one nanometer and a
definitive knowledge of molecular composition.
The material selection for biomedical and pharmaceutical applications is large and
expanding rapidly to include numerous biocompatible polyelectrolytes. Some of the more
commonly used polyelectrolytes for LbL assembly are shown in Figure 2.5.
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Figure 2.5. Biocompatible polyelectrolytes in Layer-by-Layer assembly.
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Although the LbL technique is versatile and can be used in a wide array of
schemes it is time consuming and laborious to deposit multilayer films. The method is
not amenable to scaleup due to the large number of process steps involved. Therefore,
there is a need for using materials that will modulate the desired property, such as
diffusion, by an order of magnitude and to reduce number of process steps.
One prospective material in the field of drug delivery could be the use of
phospholipids. Phospholipids have long been used in the pharmaceutical industry to
deliver drugs in vivo. Moreover the diffusion properties of lipid bilayers for hydrophilic
and water soluble molecules is low. Combining LbL assembly and liposome technology
could yield benefits that will combine the advantages of both the technologies. The LbL
technique enables the design of microccapsules of precise size, and liposomes could be
used to tune the diffusion o f these microcapsules. The concept is presented pictorially in
Figure 2.6, where a charged solid core can first be coated with two bilayers of oppositely
charged polyelectrolytes followed by alternate deposition of negatively charged
phospholipids admixed with DPPC alternated with a positively charged polyelectrolyte.
Such a scheme can be exploited to coat drug microparticles such as insulin to retard
diffusion o f drug from the core. To elaborate the scheme, a sacrificial core could be
employed to produce a hollow polyelectrolyte capsule which can be used to permeate
active drug followed by phospholipid/polyelectrolyte coating to entrap the drug for
sustained delivery.
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Scheme for lipid assembly
on hollow polyelectrolyte

Figure 2.6. Schemes showing the alternate deposition of polyelectrolytes
and phospholipids. Such architectures can impart special properties to LbL
films like diffusion control and biocompatibility.

2.5 Caleiiim Salts for Delivery of
Hydrophobic Drugs
Many

anticancer

drugs

such

as

dexamethasone,

paclitaxil,

and some

chemotherapeutic drugs are hydrophobic in nature and thus have extremely poor
solubility in water. These drugs are typically administered by an intravenous injection of
a liposome-based formulation. Although new methods are being developed for delivery
o f these drugs, such as the use o f pegylated amphiphilic molecules, these techniques
remain distant from the market and are still in preclinical trials. Effective administration
o f these drugs eliciting low systemic toxicity could be possible through the use of a nasal
delivery platform with the use o f micro- and nanoparticles. Alternatively, nanoparticlebased delivery mechanisms with slow biodegradability could be prospectively exploited
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if such drugs were entrapped in a mineral matrix of calcium carbonate. Such a system has
been demonstrated in a rat model by Uneo et al. [57] for hydrophilic drugs and peptides.
Microparticles have been used for drug delivery for the last couple of decades.
Most of the micro- and nanoparticles are organic[58] and some are inorganic [58, 59].
The use of calcium mineral salts incorporating drugs in the form of nano-microparticles
of calcium carbonate (CaC03), calcium phosphate (Ca(H2 P 0 4 )2 ), tricalcium phosphate
(Ca3(P04)2) and hydroxyapatite (Ca5 (P0 4 ) 3 0 H), have been used in drug delivery [60, 61].
CaC03 has been reported useful as a carrier of hydrophilic drugs and insulin because of
easy production and slow biodegradability [62-64]. In most of the work using calcium
salt microparticles for drug delivery, the drug has been adsorbed on the surface of the
micro- and nanoparticles. In a recent report Uneo et al. [57] have shown that both
hydrophilic and peptide drugs can be incorporated into calcium carbonate nanoparticles.
The authors further showed the feasibility of delivering the drug intravenously in rats
without eliciting a systemic toxicity. Among all the minerals used for delivery of drugs in
vivo, calcium carbonate has the highest lethal dose limit (-150 mg/kg body weight),
making it one o f the most promising candidates for drug delivery. It surpasses inert
materials such as titanium dioxide, silica and apatite in terms of body tolerance. CaC03 is
a food supplement and can be incorporated in the biochemical pathways, thus facilitating
easy clearance from the body.
Most o f the work relating to CaC03 has been in the area of study of its mineral
polymorphs and crystallization mechanisms. Ozin et al. [65, 66] have studied in great
detail the biomineralization scheme of calcium salts, particularly carbonate, apatite, and
hydroxyapatite in association with biological materials such as amphiphiles, proteins, and
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polymers. Although incorporation and adsorption of hydrophilic drugs and peptides into
the microparticles [53, 57] have been well studied and elaborated, the adsorption of
hydrophobic drugs has not. Because most new drugs for the treatment of cancer are
hydrophobic, design o f effective and convenient drug delivery methods are important.
To study the physical and chemical changes at micro- and nanoscale requires
appropriate instrumentation and suitable analysis of the results. The next section deals
with the changes to standard measurement techniques and theory associated with it. The
study of ultrathin films on flat surfaces needs characterization capable of measuring
nanometer thickness changes such as quartz crystal microbalance QCM. Changes in
colloidal particles coated with nanometer thick films can be characterized by studying the
alternation of surface charge.

2.6 Instrumentation: Theory and Practice
2.6.1 Quartz Crystal Microbalance
QCM technique is capable of measuring thickness changes less than a nanometer,
and mass changes less than a nanogram.
The following notation has been used for this subsection on the QCM.
Symbol definitions:
X - acoustic wavelength
- speed of acoustic wave
t - quartz thickness
F0 - resonance frequency of the quartz crystal
M - Mass of quartz (between the electrodes)
A - area between the electrodes
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p - density of quartz.
p q - quartz shear modulus
Figure 2.7 is a schematic of the QCM, showing a transverse section of the quartz
crystal with electrodes plated on the top and bottom of the crystal.

X /2 = tq
electrodes

Film deposition

X /2 ■ tq + tf

Figure 2.7. Transverse shear wave in a quartz crystal microbalance
where tq is thickness of the quartz crystal, tf is the thickness of the
film.

The piezoelectric effect of quartz is well known, when two electrodes are put at
different potentials, an electric field results across the QCM, i.e., in the "y direction".
Such an electric field in the "y direction" couples to shear motion "around" the z-axis,
and vice versa. The end result is that shear waves in the quartz, in which the mechanical
displacement is in the "x direction", also called the electric axis, are coupled to voltage
between the electrodes. This phenomenon is used to study deposition of ultrathin films on
quartz substrate.
In a quartz crystal which is cut along the A-T axis and coated with a fine layer of
metal to act as electrode, a potential applied to the electrodes of a QCM produces an
acoustic wave along the transverse direction, as depicted in Figure 2.7, of wavelength X.
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The Sauerbrey Equation can be derived as follows.
The wavelength is related to the thickness of the quartz can be represented by the
following relation

xn =t

(i)

* = r ,/F a

(2)

Also,

(3)
For a unit change in frequency,
AF

(4)
v7

2t

From equations M = tA p , At - AM/ A p , t = Vtr/2F^

and (1), (2) and (3) in Equation

(4) we obtain

-2 A M

AF
F0l

—

=

V .A p

(5)

This equation is called the Sauerbrey Equation
We can write Vtr =

■
>where for quartz /i?=2.95xl011dyn/cm2 and p = 2.65 g/cm3,

Z

'y

and Fo= 9x10 Hz and A - 0.16 cm for quartz crystals used in this work.
Substitution o f these values into Equation (5) results in a working equation for
measurement of the film thickness.
Discussion: The entire derivation above, and consequently the validity of
Sauerbrey Equation, is based on the assumption that the material adsorbed on the quartz
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crystal is a rigid body (it vibrates/resonates in sync with the quartz crystal), so the change
in frequency is directly correlated to the deposition of mass.
This derivation does not depend on the properties of the materials being adsorbed.
For practical purposes, such as adsorption of polyelectrolytes and nanoparticles, these
properties are unimportant because the mass of material adsorbed is < 1% of the mass of
resonator itself. This mass is equivalent to ~200 nm thick film of polymers.
Biological materials however are not rigid bodies but behave as viscoelastic
materials. Therefore, there is a delay from the time of application of shear to the onset of
deformation, so the stress/strain relation is not linear. For such materials, the change in
frequency is not proportional to the mass adsorbed. In typical situations the mass is
overestimated due to frequency attenuation. Therefore, real time decay of the resonant
frequency is used to estimate the changes in mass of the adsorbed material where
deposition in aqueous mediums can be studied.
However, in this work QCM resonance frequency changes have been used to
estimate thin film deposition with biological samples as well. To take into account the
above constraints, it has been shown by Kankare [67] that for films with a thickness less
than 45 nm, viscoelastic material such as proteins and hydrated polymers behave as a
rigid body because in such circumstances the film consists <0.1% mass of the quartz
crystal and the errors are not significant. Hence, for QCM studies of biological (soft)
materials it is not advisable to go beyond this limit.
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2.6.2 Zeta-Potential and the Theory
Involved
The equations, some statements and figures in this subsection have been reproduced from
the book titled Paul C Hiemenz, Principles of Colloid and Surface Chemistry, 2nd Ed.
Marcel Dekker, 1986. Discussion relevant to the current work is provided by the author.
A colloidal particle has surface charge attributed to it due to the presence of
charged functional groups such as carboxylate, amine, hydroxyl, oxide, and others. Such
groups cause discrepancy in surface charge of a colloidal particle or protein, and the net
surface charge of the particle as a result of all the positive and negative charges on the
surface is studied using zeta-potential.
The zeta-potential is a derived value and involves the combined effects of motion
and electrical phenomena. Zeta-potential is therefore an electrokinetic phenomenon and
is empirically equivalent to the double layer potential, and has a direct bearing on the
colloid stability.
To begin the analysis o f the formulas leading to zeta-potential and understand the
limitations we have to begin from the Debye-Hiickel Approximation:
The variation o f potential with distance from a charged surface of arbitary shape is
described by the Poisson Equation

ay ay ay _ p

ox oy

oz s •

~T~Y + ~Z~r + T T - —

(6 )

Where,
¥ is the potential, p* is the charge density (coulomb/m3) and, s is the dielectric constant
(eo sr) is product o f permittivity of free space and permittivity of the medium.
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Equation (6) can be reduced to a one-dimensional form as for charge distribution
from a planar surface
d^2y/ _
8x2

p*
£

(7)

The charge density can be expressed in terms of potential with the Boltzmann factor as
applied to ions.
n,
ni0

= exp

f

z te y /^

V

kT

(8)

where n; is the number o f ions of type i per unit volume near the surface, and n,o is the
bulk concentration, e is the charge of an electron, k is the Boltzmann constant, T is the
temperature in Kelvin and z,. is the valence of the ion and is either a positive or negative
integer. Thus charge density can be expressed as

p

= Z zien>= E zienio exp( ~ ^

(9)

Combining Equations (7) and (9) we have
d 2y/
=
~dxr

exp

r -Z je y /^
kT

( 10)

This relationship is the starting point of Debye-Huckel theory of electrolyte non
ideality, except that this relationship exists in a 3-D spherical coordinate system.This
derivation implies that potentials associated with various charges are additive.
By expanding the exponential on the right hand side of Equation (10) into a power
series and retaining only the first order terms of the equation, and by taking into account
the electroneutrality, we have,
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( 11)

Integrating,
y/ = y/0 exp(-Kr)

Where,

k2

-

A plot of —

( 12)

skT
versus distance from surface according to the Debye-Huckel

Approximation would show an exponential decrease in potential from the surface of the
microparticle. This variation of potential results in attraction or repulsion of colloidal
particles in solution, and the effective distance of interaction, in terms of molecular
distance, is called the “double layer”.
Equation (12) can be written for a spherical particle as
w - —— exp(- kt)

4nar

(13)

In the Equation (13) the potential is rewritten as a function of charge. The DebyeHuckel Approximations are strictly applicable only for low potentials. These equations
take into consideration the effect of electrolyte concentrations and valence of the charges,
and are consistent with more elaborate calculations.
Throughout the preceding discussion charged particle was treated as a point
charge without volume, but in practice they do occupy a volume and we define a “stemlayer” (Figure 2.8, stem surface) which occurs at a distance 8 from the actual surface and
is drawn through ions which are assumed to be adsorbed on the charged wall. Applying
this definition to a particle migrating in an electric field, a layer of fluid occurs on the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

42

particle surface that is immobilized and a surrounding layer on the particle occurs that
moves at the same velocity as the particle due to surface shear (Figure 2.8). The exact
distances of these layers are unknown but they are within a few molecular layers of the
particle. It is however important to note that the surface of shear occurs well within the
double layer.
Rather than identify the stem-surface we define the potential at the surface of
shear to be zeta-potential represented by the Greek symbol

A representation of these

magnitudes of potentials is shown in Figure 2.8. Simplistically ^-potential is surface
potential at surface of shear and the surface of shear is the effective particle dimension as
measured by the instrument.

—

Stern surface

r

Surface o f shear

Distance from
surface

Figure 2.8. Relative magnitudes of potentials of interest.
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Distances within the double layer are considered large or small, depending on
their magnitude relative to

k"1.

In dilute solutions, where k ' 1 is large, the surface of shear

may be safely regarded as coinciding with the surface in units which are relative to
double layer thickness. Therefore for small

k

we can write Equation (13) as

£ = -* -e x p (-* K )
AneR

(14)

where, R is the actual radius o f the particle.
Expanding the exponential we have,
1
AnsR exp(/rf?)
<7

q
1
AnsR (l + kR)

For small values of kR the above equation becomes
C =~ ^~
AnsR

(16)

Taking into accountthemotion of a spherical particle inan electric field(Stoke’s law to
account

forthedrag on the particle), the velocity of the chargedparticle

can be

represented as

(17)
V

Also, the mobility is defined as velocity per unit field and u = — , where u is the

E

electrophoretic mobility. Thus substitution of Equation (17) in (16) becomes
2<
<18)

This equation is called the Hiickel Equation.
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This equation is valid for values where k R less than 0.1, which means, that for
particles of radius R=10'8 m the corresponding concentration is about 10 pM of a
monovalent electrolyte. The product

kR

is represented in Figure 2.9 pictorially as the

Htickel limit, establishing a range of values for

k

and

R

.

This analysis assumes the particle to be a symmetrical rigid sphere with uniform
surface charge distribution. Proteins or small protein complexes such as dimers hexamers
are of the order o f ~10 nm in size, rarely have a symmetrical charge distribution, and are
not rigid bodies. Furthermore, changes in the local environment strongly influence the
structure o f the molecules/molecular complexes. The ^-potential is related to surface
potential and but is not surface potential itself. It is merely a derived value which changes
with the surface potential. Thus, the interpretation of ^-potential as an absolute surface
potential should be used with caution.
When the double-layer thickness is much smaller than the particle itself, i.e.
particles with large values of/d?, the solution of Poisson Equation and drag on the
surface of the particle yield an equation similar to Equation (18), which is

This equation is called the Helmholtz-Smoluchowski Equation.
Unlike in Equation (18), Equation (19) requires no assumptions of the structure of
the double layer. Only the Poisson Equation and bulk values of r| (viscosity) and e
(dielectric constant) apply. This equation applies for

k

R

> 100 or for particles with sizes

typically ~500nm and above. The exact applications of the above equations are depicted
in Figure 2.9, as the theoretical boundries of colloidal science. However, practical
experiments involving colloids involve particles with sizes up to 10 pm.
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Figure 2.9. The domain within which most investigations of
aqueous colloidal systems lie in terms of particle radii and 1:1
electrolyte concentration. The diagonal lines indicate the limits of
the Hiickel and the Helmholtz-Smoluchowski Equations.

Equation (19) applies to whole cell ^-potentials and large protein aggregates.
However, the Equations (18) and (19) are the lower and upper limits of the domain of
colloids (Figure 2.9) which we study. Too-large particles would make suspensions, (they
will settle over a period o f time) and too-small particles will make solutions (like ionic
moieties). Larger particles such as silica, melamine formaldehyde microparticles,
polystyrene latex microparticles, and insulin microparticles, all have applicability near
the upper limit where the Helmholtz-Smoluchowski Equation applies. On most occasions
we study suspensions using the same relations.
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It may be argued that the absolute values of ^-potentials for biological samples
obtained from the instrument are greatly inaccurate, first due to the assumptions involved
in the theory and secondly due to the inaccuracies resulting from the solid theoretical
background pertaining to such calculations. However, the ^-potential is used to study
trends during LbL nanoassembly, and absolute values by themselves have little use. Thus
under similar conditions we can safely assume the ^-potential to reflect the changes in
surface potential of the microparticle in question.
Apart from surface charge characterization using ^-potential, colloidal particles
with sizes over 1pm can be visualized using optical techniques such as confocal
microscopy. Fluorescently tagged polymers or nanoparticles aid in visualizing particles
that are not natively fluorescent.
2.6.3 Confocal Microscopy
Confocal microscope is an inverted compound microscope with laser optics,
advanced electronics, and a software analysis system to study a sample under
investigation. The primary advantage of confocal microscope is the laser light source.
Unlike a regular microscope, chromatic aberrations are avoided by using a
monochromatic light source from the laser; further, the effective resolution of the
microscope is limited only by the wavelength of light used. Resolutions up to 190 nm can
be achieved using a confocal microscope. The electronics and software included permit
complex experiments like Fluorescence Recovery After Photobleaching (FRAP), which
is illustrated in Figure 2.10 and has been employed in Chapter 4. The schematic of the
model used is presented in Figure 2.10, which shows the bleach spot indicated by light
grey color, and the region o f interest indicated by the dark gray circle. The bleach spot is
the area on the microscope slide where the laser intensity is maintained at maximum
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level. The region of interest is the area where we measure fluorescence recovery; note
that this region is inside the capsule. The development of the diffusion model used in
Chapter 4 is described here.

C apsule wall

Region of Interest w here
fluorescence intensity is
m easu red with time

_ ~10 nm thickness of
— m icrocapsule shell

L aser bleach
spot

Fluorescence
intensity in the
interior of the
m icrocapsule
averaged over a
selected a re a is
m easured l(t), and
normalized
F(t)=l(t)/l(t<0)

Figure 2.10. FRAP experimental schematic for estimation of
diffusion coefficient of microcapsules.

Development o f a working diffusion model for hollow polyelectrolyte capsules is
based on the model for Fluorescence Recovery After Photobleaching (FRAP) developed
by Axelrod et al. [68], in two-dimensional coordinates, and the use of the model to
calculate diffusion coefficient, elaborated by Blonk et al. [69] is presented later.
A two-dimensional model is chosen because the diffusion coefficient across a thin
membrane (capsule wall in Figure 2.10) is of interest in the current work.
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The following assumptions are made for the model.
1. Diffusion of the species is effected primarily by the LbL assembly of the capsule.
2. In the lateral dimensions bulk diffusion is rapid and can be ignored for practical
purposes, and the effective diffusion in the capsule interior is determined by the
diffusion properties o f the capsule walls.
3. Fluorescence intensity in the interior of the capsule (ROI Figure 2.10) at infinite
time is equal to the fluorescence intensity prior to photobleaching
m

- = m < 0-

4. For the current situation, as the microcapsules are isolated on a glass slide covered
with a cover slip, only lateral diffusion is important, and a two-dimensional model
may be used.
5. The immobile fraction is assumed to be absent.
Based on the two-dimensional model proposed by Axelrod et al. [68], the normalized
fluorescence recovery curve can be written as follows:

l + u 1+

(19)

Where,
xD is the two-dimensional characteristic diffusion time and is related to the diffusion
coefficient
D by the relation
(2 0 )
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and

cd is

the half-width of the Gaussian profile of the focused laser spot, it is usually

determined at e~2 times the height of the profile. D (cm2/s) is defined by
k T

£> = - — xlO4,

(21)

6rjr

where, k is Boltzmann’s constant, T is the temperature (K), jj is the viscosity (N.s/m2)
of the medium and r is the effective radius (m) of the diffusing particles, k is a bleach
constant and depends on the sensitivity o f the system for bleaching and is empirically
related to the percentage of bleach by
% bleach = 10 0 * '~ 1 + g
K

.

(22)

The fluorescence recovery when an immobile fraction is present, due to irreversible
adsorption, is given by
F(<) = F ( i ) { l - * ( l - /( » ) ) } ,

(23)

where F(i) is the intensity of the bleach spot before bleaching, and R is the mobile
fraction defined by
„

F (o o )-F (0 )

R = —— ----- — ,

F (0-F (0)

(24)

1 >

where F(oo) is the normalized intensity of the bleached spot at infinite time after
bleaching and F(0) is the normalized intensity just after bleaching.
However, for practical purposes the working model is designed as follows based
on the schematic presented in Figure 2.10.
The value o f co is determined experimentally to be 0.0000557, (Blonk et al.[69])
The bleach constant

k

is calculated using the modified Equation (22) as
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where IQis the fluorescence intensity of the bleach spot immediately after
photobleaching, and I l<0 is the fluorescence intensity prior to photobleaching.
Normalized fluorescence intensity F (t) is obtained and the data is fitted to Equation (19)
and

td

is estimated. Following which, an estimate for the diffusion coefficient is made

using Equation (20).
2.6.4 Thermogravimetric Analysis
For a mixture of organic and inorganic samples or for inorganic samples
containing thermally decomposable constituents, thermogravimetric analysis (TGA)
provides a tool for quantitatively estimating the decomposable constituents. TGA relies
on the principle o f thermal decomposition of the material. The thermal decomposition or
evaporation of solid products into gaseous form usually occurs at a temperature
characteristic of that material. For example, during the decomposition of CaC0 3 , it
breaks down into CaO and CO2 . However, organic material may be thermally
decomposed into numerous products depending on the length of the carbon chain and
other radical groups present. Pictorially, the working of the thermogravimetric
measurement is shown in Figure 2.11, where a sample is heated at the rate of 5 °C/min
and the resulting changes in mass are recorded.
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Change in mass with
Temperature measured
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5 degrees per minute

Figure 2.11. Principle of thermogravimetric analysis: a sample is
heated at a fixed rate and mass changes are recorded with changes
in temperature.

Thermogravimetric analysis can thus be used to estimate the thermal
decomposition temperature o f different materials with the same or different
stoichiometric composition. It allows the determination of strength of covalent and other
linkages in the material.
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CHAPTER 3

SURFACE MODIFICATION OF INSULIN MICRO
PARTICLES USING ELECTROSTATIC
LAYER-BY-LAYER ASSEMBLY

3.1 Introduction
Due to the success o f biotechnology development, proteins represent the fastestgrowing segment o f pharmaceutical products, but delivery of proteins in a controlled
manner is a major challenge. Controlling the rate o f release of the therapeutic agents from
delivery devices offers prolonged therapeutic levels of the protein, improved
pharmacokinetics and pharmaco-dynamics, and increased patient convenience and
compliance. A variety of drug delivery approaches has been developed over the years to
control release. Conventional methods include spray drying, spray freeze drying, milling,
nondegradable and degradable polymeric systems, etc. The drawbacks of these methods
are the use o f organic solvents which are often incompatible with proteins, the
complexity, and cost-ineffectiveness as discussed in great detail in the background
material.
EPIC Therapeutics Inc. developed a simple, scaleable water-based process of
microsphere formation via controlled phase separation of macromolecules with water
soluble polymers that generates microspheres PROMAXX® with a narrow size
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distribution [70, 71]. The template PROMAXX® microparticle can consist of protein,
peptide, nucleic acid, polymer, or low molecular weight compound. The aim of
thecurrent research is to apply (LbL) assembly of oppositely charged polyelectrolytes on
PROMAXX® insulin microspheres as a continuation of the particle formation process to
obtain sustained release and control of surface functional properties.
The initial fundamental research on LbL assembly was performed on planar
substrates. However, the LbL process is not limited to coating on large surfaces. The
nanofilms may be deposited on tiny (micro- or nano-) three-dimensional templates [48,
51, 72-74]. Functional nanocomposite films deposited on these colloidal carriers enhance
biocatalytic reactions and allow controlled release of the encapsulated compound due to
adjustable thickness o f the capsule walls. The microparticles can be separated from
polyelectrolytes after adsorption saturation, which is achieved via centrifugation or
filtration. Latex, inorganic microparticles, and some drug microcrystals (1-5 pm
Furosemide, Ibuprofen, Indomethacin, and Dexamethasone particles) have been
nanocoated with linear polyelectrolytes with 5-12 polycation/poly anion bilayers, which
gives capsule wall thicknesses of 20-100 nm [54, 56, 75-78]. Release time for these drugs
was increased from ca 1 min for bare crystals to 1-3 hours for 8-10 bilayer encapsulation.
10 pm insulin microcrystals also were encapsulated in 15 polylysine/sodium alginic acid
multilayers, providing 10 times longer dissolution as compared with bare crystals.
However, with less than 10 polyelectrolyte bilayers the release rates of bare and coated
insulin microcrystals were similar [79, 80]. The nano-organized shell around drug
microparticles was considered in these works as an adjustable diffusion barrier, and
specific interaction with microcores was not considered. In another approach,
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interpolyelectrolyte complexation of drugs with polyelectrolytes to form microparticles
spontaneously, was developed [81] but LbL assembly was not used.
In this work the combination of interpolyelectrolyte complex formation and
organized multilayer shells are used to encapsulate 2 pm diameter PROMAXX insulin
particles for controllable prolonged release. It was found that formation of 10-100 nm
LbL multilayers on soft semi-soluble and permeable PROMAXX® insulin cores was
insufficient to provide a significant physical barrier to slow the diffusion of insulin from
the core into aqueous solution. Conditions for complexation of the outermost part of the
insulin microparticles with the first polyelectrolyte layer were established, which played a
critical role for sustained release, by decreasing the release rate of drug from the
polyelectrolyte-complexed microparticle (Figure 3.1). Further polycation/polyanion
multilayer assembly allowed fine adjustment of the insulin release profile (Figure 3.1).
The odd polycation layers reinforced the microparticle complex, and even polyanion
cores weakened the complex. The overall effect was a cumulative decrease in the release
rate with increase in total number o f odd polyelectrolyte layers.
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Figure 3.1. A schematic illustration of the assembly of polyelectrolyte layers on
insulin PROMAXX® microspheres at pH 7.0.

3.2 Experimental Methods
3.2.1 Materials
Chondroitin sulfate C sodium salt (ChS, from shark cartilage), poly-l-glutamic
acid sodium salt (PGlu, MW 17000), poly-l-aspartic acid sodium salt (PAsp, MW
33400), poly-l-lysine hydrochloride (PLys, MW 22100), protamine sulfate (ProtS,) and
poly-l-lysine hydrochloride fluorescein-labeled (PLys-FITC) were purchased from Sigma
and

used

as

received.

Poly(sodium-4-styrene

sulfonate)

(PSS,

MW

70000),

carboxymethyl cellulose (CMC, MW 70000), poly(diallyldimethyl ammonium chloride)
(PDDA, MW 200000), and polyallylamine hydrochloride (PAH, MW 70000) were
purchased from Aldrich and used as received. Dextran sulfate sodium salt (DexS, MW
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500000) was purchased from Fluka, and poly-l-arginine hydrochloride (PArg, MW
20000) from MP Biomedicals Inc.
PROMAXX® insulin microparticles (EPIC Therapeutics, Lot# 300X17) were
used as cores. The microparticles were fabricated using EPIC’s proprietary Controlled
Phase Separation (CPS) technology and the resulting suspension was frozen and stored at
-20°C until used. The LbL coating process was conducted in an aqueous solution
composed of 16% polyethylene glycol MW 3350 kD (PEG 3350) and 0.7 % NaCl unless
otherwise noted. The pH of this solution was adjusted to a desired value using either
hydrochloric acid or sodium hydroxide.
3.2.2 Layer-bv-Layer Coating of
Insulin Microspheres with
Multiple Polvelectrolyte
Lavers
Before LbL coating, 20 mL aliquots of insulin microparticles were thawed at
ambient temperature to melt previously frozen samples. The suspension of microparticles
was then kept on ice (-2° C) during the entire procedure. Insulin microparticles with
average diameter of 2 pm were separated from the supernatant by centrifugation at 2500
rpm (Eppendorf 5804R), and the buffer was replaced with an equal volume of fresh
buffer that was used for the set of experiments. The following buffers were used: (a) 16
% PEG-0.7 % NaCl buffer with pH adjusted to a desirable value (5.8 or 7.0), (b) 16 %
PEG-0.7 % NaCl, pH 7.0, containing 0.026 % ZnCl2 to reduce solubility of insulin, and
(c) 0.16 % PEG, 1.3xl0'3 % acetic acid 0.026 % ZnCl2, pH 7.0 buffer.
For deposition of the first poly electrolyte layer, polyelectrolyte solution was
added to insulin microparticles suspended in the 20 mL of buffer and thoroughly mixed.
The final concentration o f the polyelectrolyte in the supernatant solution was between
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0.005 and 1.5 mg/mL. After 60 min adsorption of the first polyelectrolyte layer, the
microparticles were separated from the supernatant using centrifugation; the supernatant
was removed and the microparticles were re-suspended in fresh buffer. The
centrifugation / re-suspension cycle was repeated twice to remove traces of unadsorbed
polyelectrolyte. The second polyelectrolyte layer with the charge opposite to that of the
first polyelectrolyte layer was assembled by repeating the procedure above. Multiple
layers of polyelectrolytes were adsorbed by repeating the procedure.
3.2.3 Quartz Crystal Microbalance
Measurements
The quartz crystal microbalance (QCM) method was used to elaborate LbL
assembly in the presence o f PEG at different temperatures and estimate the thickness of
the layers. A precursor film o f (PAH/PSS)n films (n=2-4) was deposited on 9 MHz silver
QCM resonators. Polyelectrolyte and protein layers were assembled from 1 mg/mL
solutions o f the substances in corresponding buffers. The time for deposition was 15 min
or 1 hour per layer; the temperature was 2 °C (in melting ice). The QCM resonator was
rinsed with DI water and dried in a stream of nitrogen after absorption of each layer. The
frequency changes (AF) o f the resonators was monitored using an universal counter
(Agilent) with an attachment (USI-System, Japan) adapted for QCM resonators and
translated into the thickness using the Sauerbrey Equation with the experimental scaling:
At(nm) = -0.016AF (Hz) [52],
3.2.4 Microparticles Zeta- Potential
Measurements
Zeta-potential measurements of microparticles were taken using a Brookhaven
ZetaPlus microelectrophoretic system. For ^-potential measurements, 40 pL of the
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sample under investigation was added to 2.0 ml of buffer, mixed, and the suspension was
analyzed immidiately. The temperature of the cell was equilibrated to 8 °C to avoid the
dissolution of PROMAXX® insulin particles. In calculations of the ^-potentials using the
Smoluchowski Equation, increased solvent viscosity due to the high (16 wt %) PEG
concentration was taken into account.
3.2.5 Confocal Laser Scanning
Microscopy
Confocal images of PROMAXX® insulin microspheres were taken with a
confocal laser scanning microscopy (Leica DMI RE2) equipped with 63x oil objective.
Fluorescent labeling o f ProtS and PLys with FITC were performed with the standard
procedure [82, 83].
3.2.6 In Vitro Release Study
Dissolution o f insulin microspheres was studied by addition of 10 ml of the
release buffer (10 mM Tris, 0.05% Brij 35, 0.9% NaCl, pH 7.4) into glass vials
containing 3 mg equivalence of the insulin microspheres, and incubation at 37°C. At
designated time intervals 400 pL of the medium was transferred into a microfuge tube
and centrifuged for 2 min at 13000 rpm, and 300 pL of the resulting supernatant was
removed and stored at -80°C until analyzed. The 300 pL of fresh medium was added to
the remaining portion o f the collected sample, the pallet was reconstituted, and was
transferred back to the corresponding in vitro release medium. The amount the released
protein was estimated with the bicinchoninic acid (BCA) assay.
To determine protein content, a known amount of microspheres was suspended in
1.0 ml 0.01 N HC1. The medium was centrifuged at 13000 rpm for 5 minutes at 4°C. The
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protein content in the supernatant was determined by BCA assay, using solutions of
insulin in 0.01 N HC1 to construct the calibration curve.

3.3 Results and Discussion
3.3.1 Electrostatic LbL Assembly
in the Presence of PEG
In earlier works on LbL assembly, experiments to determine the feasibility of
LbL assembly of polyelectrolytes in the presence of high concentrations of other
hydrophilic macromolecules had not been performed [47,48, 74].
Therefore, first it had to be determined whether polyelectrolytes and proteins
could be assembled in aqueous solutions containing up to 16 % PEG, which is necessary
for insulin microparticles’ stabilization. Figure 3.2(a) shows a linear step-by-step increase
o f film thicknesses for different poly electrolyte films assembled in 16 % PEG-0.7 %
NaCl, pH 5.8 and at room temperature. Stable growth of the films is observed for
different polyelectrolyte combinations. The assembly of polyelectrolytes in the presence
o f PEG resulted in thicker films, compared with LbL films obtained in DI water without
any polymer additives, and had a typical bilayer thickness of ca. 2-11 nm (Table 3.1).
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Table 3.1. Bilayer thickness (in nm) for polycation / polyanion assemblies in
16% PEG-0.7% NaCl, pH 5.8, room temperature, 15 min per layer.
Polyanions

Polycations
PLys

PArg

ProtS

DexS

4.9±1.0

4.2±0.8

5.0±1.5

ChS

6.3±2.0

11.3±3.9

5.4±1.4

Alginic acid

6.7±2.2

6.7±2.3

1.8±0.4

PEG is well known as a complexing and aggregating agent, which induces bulk
coil conformation in polypeptide and DNA molecules [84]. Therefore, the presence of
PEG can increase polyelectrolyte layer thickness.
Therefore it can be concluded that electrostatic LbL assembly of polyelectrolytes
and proteins can be carried out in the presence of hydrophilic uncharged polymers. In
related work, a competitive adsorption of polyelectrolytes from binary mixtures was
recently reported [85, 86].
3.3.2 Influence of Temperature on
LbL Assembly in the
Presence of PEG
To prevent undesirable dissolution of the microparticles, the LbL assembly was
performed in the temperature range of a low 2-5 °C. The influence of low temperature on
polyelectrolyte assembly in the presence of PEG was investigated for DexS and PLys
combination using QCM. At 2° C, the assembly still occurs, but the bilayer thickness
after 15 min deposition is much lower than that for the same combination at room
temperature (0.6 nm vs 4.9 nm). The thickness of a polyelectrolyte bilayer was restored
by increasing the adsorption time to one hour to achieve a thickness of 2.2 nm for a
DexS/PLys bilayer. Similar results were obtained for other polycation / polyanion pairs.
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All QCM resonators were initially coated with several PSS/PAH bilayers to create
a uniformly charged surface and to mimic the surface of the microparticles under
investigation (Figure 3.2(b)). The bilayer thickness for the films assembled in 16 % PEG0.7 % NaCl buffer, pH 5.8 is between 1 and 5 nm depending on composition (Table 3.2).

Table 3.2. Bilayer thickness (in nm) for polycation / polyanion assemblies
inl6% PEG-0.7% NaCl, pH 5.8, 2 °C, 60 min per layer.
Polycations
Polyanions

PLys

PArg

ProtS

Gelatin B

Chitosan

ChS

2.3±0.3
1.4±0.3

1.8+1.2
3.2±0.4

1.110.2
1.5±0.2

4.811.1
1.810.4

3.210.2
2.710.5

PAsp

1.3±0.1

5.1±0.5

1.310.2

PGlu

4.310.7

3.710.5

1.010.1

DexS

It can be assumed that intermediate rinsing with DI water done after adsorption of
each layer removes most o f the hydrophilic PEG, making the final structure of the films
close to that obtained in the absence of PEG. At the same time, as can be seen from Table
3.1 and Table 3.2, the experimental errors observed for different combinations are 10-15
%. This variation can be associated with trace amounts of PEG varying from layer to
layer in the films due to minute differences in film rinsing.
In some o f the QCM experimental series, to simulate conditions closer to
deposition on insulin microcores, an insulin layer was additionally deposited on the top of
the PAH/PSS precursor to simulate conditions closer to the assembly on insulin cores
(Figure 3.2(b), seventh assembly step). The thickness of the insulin layer was 4.5 ±1 .0
nm, which corresponds to adsorption of ~2 monolayers of insulin. As insulin is positive
at pH 5.8, the insulin layer was followed by a polyanion layer. A slight decrease in film
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thickness was observed for all films as the insulin layer was partially removed.
Polyanions peel off some loosely attached insulin molecules and adsorb on the top of the
films, since it was observed that the film thickness increases again with assembly of the
next polycation layer. This behavior is common in protein/polyelectrolyte LbL assembly
[52], To conclude this section, the conditions desirable for coating of insulin microcores
were determined as 2 °C and 60 min per layer deposition and are used hereafter.
3.3.3 Coating PROMAXX®
Insulin-Microspheres with
Polvelectrolvtes
Figure 3.3 shows the surface charge reversal of insulin microparticles after
adsorption of single layers o f different polyelectrolytes at 2 °C. Further, the results for
assembly are described 1) at pH 5.8, below isoelectric point of insulin where
PROMAXX®-microcores are positive, and 2) at pH 7, above its isoelectric point
(apparent pi = 5.9) where PROMAX® insulin microparticles are negative.
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3.3.3.1 pH 5.8. positive core
At pH 5.8, insulin microparticles are positively charged and negative
polyelectrolytes as PSS, PAA, ChS, DexS, Alginic acid, PGlu, PAsp were chosen to be

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

65

adsorbed as the first layer. After polyanion adsorption, the surface charge of
microparticles changes to a negative value, indicating a successful deposition. Then a
polycation, for example PLys, was adsorbed as the second layer and the surface charge of
the microparticles reversed. Insulin microparticles coated with different polyanions as the
first layer and PLys as the second layer show varying magnitudes of positive charge. This
variability could result from the interaction of PLys with the polyanion layer, which
affects the amount o f adsorbed PLys, its structure, and ionization.
3.3.3.2 pH 7.0, negative core
Figure 3.3(b) presents the results of coating insulin microparticles at pH 7.0,
above the isoelectric point o f insulin. At this pH, the microparticles were negative, and
polycations were used as the first layer. After polycation adsorption, the charge of
microparticles changes to a positive value (left side, Figure 3.3 (b)), indicating successful
adsorption onto the microparticle surface. In the following step, a polyanion can be
adsorbed as the next layer (right side, Figure 3.3(b)).
By alternating positively and negatively charged polyelectrolytes, a multiple
coating consisting of 3-5 polyelectrolyte layers was formed on PROMAXX® insulin
microspheres. Figure 3.4 shows monitoring of surface potential for some shell
compositions that are potentially interesting for encapsulated PROMAXX® particles.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

66

>
E
m
■ 4 ft

c

©

//

4 ft

-20
s

Cfl

Layer
PLys

20

>

ProtS

ProtS
*

g

«
_9Q-

Insulin

ChS

ChS

-60

Layer
Figure 3.4. Surface charge alternation for insulin microparticles
coated with multiple polyelectrolyte layers at, (a) pH 5.8 and (b)
pH 7.0.

More than one pair of polycation and polyanion can be used to coat a
microparticle, providing a complex shell composition. Such a complex architecture
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increases the number of variants in designing shells with different properties and provides
better control over microparticles’ dissolution profile. Formation of multilayered coatings
on the microparticles is complicated by insulin dissolution, which slowly occurs, even at
low temperature. The amount of insulin remaining in the samples decreases after
deposition o f each layer. More than 50 % loss of insulin was found for a sample after
completing the deposition procedure corresponding to 3-4 polyelectrolyte layers
corresponding to 6-8 hrs of processing time. This loss makes assembly of the capsules
with more than two polyelectrolyte bilayers undesirable because of low yield of the final
product.
3.3.4 Optimization of the
N anoencapsulation
Conditions
The dependence of ^-potential on total concentration of polyelectrolyte in the bulk
is shown in Figure 3.5. With the 20 ml aliquots of insulin-microparticles in PEG buffer as
basis, and a working volume of 20 ml in the PEG buffer, the concentration of the
polyelectrolyte forming the outermost layer was varied in the range of 0-1.5 mg/ml. The
plot with closed diamonds represents the ^-potential with a single layer of ProtS. The
other plots represent the effect ChS (open circle) and CMC (closed triangle) in Figure
3.5, after a ProtS layer. ProtS as a third layer (closed square) is adsorbed after sequential
assembly of ProtS and CMC.
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3.3.4.1 pH 7.0. negative core
A complete charge reversal for cationic ProtS adsorption on negative microcores
(Figure 3.5) is observed only for solutions with concentrations higher than 0.3 mg/mL.
Lower concentrations o f ProtS are not sufficient for recharging of the microparticles’
surface. This observation is different from those made previously for LbL assembly in
aqueous solutions in the absence of PEG, where a polyelectrolyte concentration as low as
0.001 mg/mL was enough to form a saturated polyelectrolyte layer [45, 47]. A similar
dependence was found for adsorption of the second polyanion layer (Figure 3.5).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

69

3.3.4.2 pH 5.8, positive core
The concentration needed for complete charge reversal in the case of anionic
CMC and ChS is also elevated. For CMC, the minimal concentration level is around 0.1
mg/mL and for ChS it is 0.3 mg/mL.
In both cases, the degree of ionization of polymer functional groups and the
charge density on the polymer chains determine the polyelectrolyte concentration needed.
Competition between adsorption of PEG and polyelectrolytes could probably explain the
increased concentration o f polyelectrolytes needed for the LbL assembly in 16 % PEG as
compared with aqueous solutions. Besides, it may indicate that the amount of insulin
interacting with polyelectrolytes is not limited by the protein molecules located on the
surface. Taking into account the properties of microparticles, permeation of
polyelectrolytes into the microparticle interior and formation of complexes deeper within
insulin microsphere matrix can be expected. The permeation of polyelectrolytes into the
microparticles could increase the polyelectrolyte concentration needed to cause charge
reversal o f the microparticles.
3.3.5

Polvelectrolvte Interaction with
Microparticles

3.3.5.1 At p H 7.0
The interaction o f polyelectrolytes with microparticles can be visualized using
confocal microscopy using fluorescently labeled polyelectrolytes. Figure 3.6 (a) shows a
confocal fluorescence image of insulin microparticles covered with one layer of FITClabeled ProtS at pH 7.0 when core particles are negative. One can see that FITC-ProtS
fluorescence emanating from a ring around the microparticle. The interior of
microparticles is also partially fluorescent and the fluorescence intensity profile (Figure
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3.6

(a)) shows that intensity of interior is of about 20 % of that of the walls indicating that

some amount of ProtS-FITC forms complex with the insulin in the core matrix.

Figure 3.6. Confocal images of insulin microparticles coated with,
a) FITC-ProtS layer in 16 % PEG-0.7 % NaCl, pH 7.0; and (b)
PSS/FITC-PLys at pH 5.8.

3.3.5.2 At pH 5.8
At this pH microparticles are positive, and negative PSS was used as the first
layer, followed by FITC-labeled polycation, PLys. Again, narrow fluorescence rings
occur around the microparticles in the confocal microscopy image (Figure 3.6 b). We
conclude that the fluorescently labeled polyelectrolyte is attached to the microparticle
surface, but some fluorescence in the microparticle interior was also observed.
3.3.6 Modification of Microparticle
Solubility
Unmodified insulin microparticles dissolve rapidly in a physiological solution. A
large shift o f pH from 5.8 (pH o f the insulin suspension) to 7.4 (dissolution pH) with
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simultaneous increase in temperature from 2 to 37°C makes the dissolution of insulin
virtually instant. Therefore, we studied encapsulation at lower pH 5.8 and at higher pH
7.0.
3.3.6.1 pH 5.8, positive core
This pH is close to the apparent isoelectric point of insulin in the 16% PEG, 0.7%
NaCl buffer. Polyanions were adsorbed as the first capsule layer. In spite of alternation of
surface charge at these conditions, dissolution tests did not show significant reduction in
release rate with the deposition of different assemblies of charged polyelectrolytes
(Figure 3.7).
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Figure 3.7. Cumulative in vitro release of insulin from
microparticles coated with CMC and ProtS up to two bilayers at
pH 5.8 .The control is uncoated microparticles suspended in PEG
buffer at pH 5.8.

Microparticles coated with a single layer of polyanion show solubility similar to
that of an unmodified sample. At the same time, the next polycation layer decreases the
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amount of insulin released to -6 0 %. At this pH the solubility of insulin microparticles
coated with a polycation layer as the outermost layer is somewhat lower than that of
microparticles with a negative outermost layer, but this dependence is not pronounced.
3.3.6.2 pH 7.0 negative core
At this pH, insulin microparticles are negative and different polycations were used
to form the first layer (Figure 3.8).
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For such modified microparticles the initial release is still rapid. Insulin
concentration in solution reaches saturation after 30 min. However, in many cases, the
release level is much lower than

1 0 0

%, which implies that most of the insulin is fixed

inside the microparticles due to complex formation with polyelectrolytes. It is known that
a single polyelectrolyte layer does not form a diffusion barrier on the surface [48, 74].
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Polycations with charged flexible side chains, such as PAH, PArg, and PLys, slow down
the release to a larger degree than PDDA or chitosan having the charged groups on the
main polymer chain. The action of ProtS can be attributed to its chemical structure,
which, predominantly consists of Arg and Lys residues. A polyanion layer deposited on
top of the polycation changes solubility of microparticles, increasing it up to 80-100%
(Figure 3.9).
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Figure 3.9.
Cumulative in vitro release of insulin from
microparticles coated with ProtS as the first layer and subsequent
layers o f polyanions- PAsp and CMC at pH 7.0. The control
represents uncoated microparticles.

The effect o f different polyanions is not as pronounced as the action of the first
polycation layer. If a polycation is adsorbed as a third layer, the solubility of the
microparticles decreases again. Coating of insulin cores at pH 7.0 (when the core is
negative) with a polycation fixes the insulin in the core; addition of a polyanion relaxes
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the structure and allows for complete release. The third layer of polycation again
strengthens the shell-core complex. The QCM studies demonstrated that there are no
specific features of polycation/polyanion multilayers assembled on a solid support.
Therefore, formation of interpolyelectrolyte, and insulin-polyelectrolyte complexes in the
microcore are responsible for such release profile. The dissolution properties of
microparticles follow the same trend for all investigated polyelectrolyte combinations
investigated.
•

•

•

Insulin microparticles can be coated by LbL in the buffers containing Zn

.

ions,

which have an important influence on the synthesis and action of insulin in body [87].
Zinc decreases general solubility of insulin but does not change the general influence of
polyelectrolytes on microparticle dissolution. At pH 7.0, the effect of polycation and
polyanion layers deposited on the microparticle surface on dissolution of microparticles
is similar to that in obtained without Zn2+ ions.
Therefore, the dissolution properties of insulin microparticles can be controlled by
alternating polyelectrolyte layers on microparticles’ surface. If coating pH and
dissolution pH are on the same side of the isoelectric point (e.g., test pH 7.4 and coating
pH 7.0 for insulin with pi 5.9), a polymer with opposite charge (a polycation above
isoelectric point and a polyanion below it) decreases dissolution of the microparticles due
to formation of electrostatically bound inter-polyelectrolyte complex between these
macromolecules. The second polyelectrolyte layer competes with insulin for the
previously adsorbed polyelectrolyte and thus weakens its interaction with the protein. The
concept o f a diffusion barrier formed by polyelectrolyte multilayers is less applicable for
thin coatings consisting of 3-4 polyelectrolyte layers.
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3.3.7 Effect of Polvion
Concentration on Release of
Insulin from Microparticles
It has been shown that surface properties of microparticles can be changed by
varying polyelectrolyte concentration in coating solutions. The influence of concentration
on microparticle dissolution is shown in Figure 3.10.
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Figure
3.10.
Concentration dependence
of outermost
polyelectrolyte layer on insulin release in vitro after 48 hours from
insulin microparticles coated with different polyelectrolyte
concentrations in 16 % PEG-0.7 % NaCl pH 7.0.

For a single ProtS layer, the dissolution level reaches a plateau at around 0.3
mg/mL. The relationship between dissolution and concentration parallels the relation ship
between ^-potential and concentration in Figure 3.5. As soon as the polyelectrolyte
concentration is enough for complete charge reversal of microparticles’ surface, the
dissolution of the microparticles reaches a saturation level and depends only slightly on
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further increase in concentration. A similar situation is observed for the second layer. For
CMC or ChS at a concentration lower than 0.3 mg/mL, percent release is proportional to
the amount of polyelectrolyte in the supernatant and almost reaches a maximum at 0.5
mg/mL. The deposition of the third layer, ProtS from a 1.5 mg/mL solution, brings the
degree of dissolution back to a minimum. Varying supernatant concentrations during
adsorption process helps to control insulin release from the microparticles.
The yield of the final product relative to the initial amount of protein used is an
important parameter in developing sustained release drug formulations. The total insulin
amount in the samples decreases with addition of new polyelectrolyte layers due to the
losses during coating. Most of the losses occur when the samples are coated with a
polyanion layer. Therefore, to avoid the waste of insulin from PROMAXX®
microparticles, the conditions favoring low dissolution must be employed during LbL
assembly. At pH 7.0, elevated polycation concentrations and lower polyanion
concentrations are optimal.

3.4 Conclusions
Nanoorganized encapsulation of protein microcores in the presence of high
concentration of neutral polymers (PEG) was elaborated with LbL assembly. Uncoated
insulin PROMAXX® microparticles formed by controlled phase separation from
hydrophilic compounds dissolve rapidly if PEG concentration is decreased. LbL
encapsulation extended insulin release time from PROMAX®. After the first layer of
oppositely charged polymer is formed over the insulin core, the microparticle is stabilized
and new polyelectrolyte layers can be added. Balancing strong interaction of the first
polyelectrolyte layer with the protein microcore, and easing this interaction by depositing
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the second oppositely charge polyelectrolyte (polyanion/polycation for positive cores at
pH 5.8, and polycation/polyanion for negative cores at pH 7.0) allowed us to control
complexation of the encapsulated proteins and to achieve a sustained release of insulin.
The release profile was fine tuned by adding the third and fourth polyelectrolyte layer.
Therefore, the general idea of the controllable complex formation is as follows:
adsorption of the first polyelectrolyte layer results in strong complex formation and slowrelease. An addition of the second, oppositely charged polyelectrolyte layer, results in
relaxed complex and quicker release. The third oppositely charged layer again gives
slower release, and so on. Simple increase in thickness of the capsule walls in the range
of 5-10 bilayers (30-60 nm) does not slow insulin release from the microparticles. With
this, we converted the concept formulated in a Max Planck Institute’s research group [48,
72, 73, 75, 76] where a LbL multilayer was considered as a tight diffusion barrier with
adjustable thickness in the range of 5-12 bilayers, to the new approach where the main
role in the controlled release from protein micro aggregates is the adjustable
interpolyelectrolyte complex formation controlled by alternate polycation / polyanion
coating o f 2-3 monolayers.
In this chapter it was shown that a polyelectrolyte-complex on the outermost
protein layer of the drug microparticle controls of release properties of the drug. In the
next chapter we will see an alternate method for control of diffusion of small hydrophilic
molecules from hollow polyelectrolyte microcapsules.
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CHAPTER 4

LAYER-BY-LAYER ASSEMBLY USING PHOSPHOLIPIDS
AS A DIFFUSION BARRIER

4.1 Introduction
Conventional liposomal drug delivery is a well established method for in vivo
delivery of pharmaceutical compounds with focus on injectable delivery forms. However,
choice o f materials for liposomal shells is limited. One way to create precise control with
liposomal delivery methods would be to use phospholipids with the LbL technique to
blend the biocompatibility o f liposomal delivery with the versatility of LbL technique for
making thin films and hollow shells. LbL assembly of amphiphilic molecules and
polyelectrolytes can yield biomimetic systems for various applications[48,

8 8

, 89]. The

assembly of lipid bilayer membranes alternated with polyelectrolytes has been
demonstrated on solid supports [3, 90, 91]. The polyelectrolyte/lipid architecture formed
as microcapsules can have some advantages over liposomes due to better structural
support and control over size o f microcapsules [3, 91].
A lipid membrane onto solid or polymer-precoated templates can be created by
direct vesicle fusion [3, 92-95] and the Langmuir-Blodgett technique [90, 92-96]. In both
cases electrostatic forces play an important role in film formation. By vesicles (liposome)
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adsorption, a uniform lipid bilayer forms rapidly, within 5 min after addition of solution
to substrate, and covers more than 95% of the surface [92-96]. The almost perfect bilayer
coverage was shown on negatively charged silica for neutral zwitterionic lipids and their
mixtures with low concentration of negatively charged lipids. A uniform bilayer was also
shown for lipid on mica and polyethylenimine-supported surfaces [92-96]. In some cases
adsorption of more then one lipid bilayer on polycation coated surfaces was deduced
from the thickness of the obtained films [3,91].
Here, we report results of direct coating of polyelectrolyte microcapsules with
lipid layers o f different composition, and the first quantification of its influence on
capsule permeability using the fluorescence recovery after photobleaching (FRAP)
technique. The polyelectrolyte/lipid microcapsules, with controlable permeability, is of
interest for drug delivery applications.

4.2 Experimental
4.2.1 Materials
The lipids—

l,2-dipalmitoyl-s«-glycero-3-phosphatidylcholine (DPPC), 1,2-

dipalmitoyl-sM-glycero-3-phosphate

(DPPA),

L-a-phosphatidylglycerol

(PG),

L-a-

phosphatidylcholine (PC) were purchased from Avanti Polar Lipids, polyethyleneimine
(PEI MW 30,000), polyallylamine hydrochloride (PAH, MW 70,000), poly(dimethyl
diallylamide hydrochloride) (PDDA, MW 100-200,000), polystyrenesulfonate (PSS MW
70,000), fluorescein isothiocynate(FITC) labeled Dextran (FD, MW 4000) and
chloroform were purchased from Sigma and chitosan was obtained from Wako Fine
Chemicals Japan. Polymethacrylate (PMA, 3 pm) were obtained from Fluka, manganese
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carbonate microparticles were synthesized in the lab with the procedure elaborated by
Shchukin et al. [77].
4.2.2 Preparation of Unilamellar
Liposomes
Unilameller vesicles of DPPC containing 5, 10, 17, 20 % (w/w) of DPP A and
those of PC with 10, 20% (w/w) of PG were prepared by mixing the reagents in
chloroform followed by solvent evaporation. The lipid cake was hydrated using
Deionized (DI) water to obtain a concentration of 1 mg/mL solution of liposomes in DI
water, and the mixture was subjected to ultrasonication, followed by extruding the
liposomes using a 0 . 2 pm nylon filter to obtain unilamellar liposomes.
4.2.3 Preparation of Polvelectrolvte
Solutions
PEI, PAH, PDDA, and PSS were prepared as a 2 mg/mL solution in DI water at
pH 6.5 and used without further purification. Chitosan is sparingly soluble at normal pH,
so it was dissolved in 0.1 N HC1, and the pH of the solution was adjusted to pH 6.5 with
concentrated NaOH prior to use.
4.2.4 Assembly on Quartz Crystal
Microbalance
Negatively charged lipid layers were deposited from 1 mg/mL suspensions in
alternation with PEI, PAH, PDDA, and chitosan on silver QCM resonators [46], The
resonators were coated with three PAH/PSS bilayers as precursor layers. Frequency
change o f the resonators was measured only after deposition of polyelectrolyte layers to
prevent rearrangement of lipid bilayers due to drying.
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4.2.5 LbL Assembly on PMA
Microparticles for C-Potential
Studies
For each set of polymers 10 pi PMA microparticles were taken in a
microcentrifuge tube and 1 mL of 2 mg/mL polyelectrolyte or 1 mg/mL of phospholipid
solution was added and the particles were allowed to stand for 15 minutes to complete the
adsorption step. Following the adsorption step, the microparticles were centrifuged at
4000 rpm for 10 minutes and the supernatant discarded to remove excess of material in
solution. The pellet was resuspended in 2 mL DI water and the procedure repeated three
times in all to remove excess polyelectrolyte/ lipid in the solution phase. After, rinsing
the particles three times, surface charge (^-potential) measurements were taken to check
for alternation of surface charge.
4.2.6 Phospholipid Coatings on
Hollow PAH/PSS
Microcapsules and
Measurement of Diffusion
Coefficient of the Capsule
Wall
For capsule preparation, 0.2 mL of 3 mg/mL PAH and PSS solutions in 0.5 M
NaCl at pH 6.5 was added alternately to 15 mL of a suspension containing 25 mg of
MnCC>3 cores with a mean diameter of 5.5 ±0.3 nm (SEM microscopy). After 15 min
adsorption of each layer, the particles were rinsed with deionized water three times. The
cores were dissolved with 0.1 M HC1. The traces of Mn2+ were removed by washing with
a 0.1 M ethylenediaminetetraacetic acid solution and deionized water. The empty
capsules, after dissolution o f the inner cores, can be slightly swollen or shrunken
depending on the media they are in and the presence of other substances.
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The operation sequence proposed by Moya et al. [3, 91] was employed to coat
capsules with a lipid bilayer for FRAP experiments. The hollow (PSS/PAH)s capsules
with an outermost PAH layer were suspended in a 10 pM solution of FITC-dextran of
MW 4300 for 2 h to enable uniform distribution of the dyed polymer throughout the
interior of the capsules and surrounding solution. This step was followed by the addition
of lipid vesicles to form the outermost layer on the polyelectrolyte capsules. The capsules
were then rinsed with FITC-dextran solution in order to remove any unabsorbed
liposomes from the mixture. The final sample for FRAP experiments was a suspension of
capsules coated with a lipid layer in a solution of FITC-dextran. Single capsules were
isolated under a Leica confocal laser scanning microscope, photobleached, and the
fluorescence recovery after photobleaching was monitored [97].
The diffusion in the individual capsules was studied by using a molecular
diffusion model based on fluorescence recovery developed by Axelrod and co-workers
[6 8 , 69] as described in Chapter 2.

4.3 Results and Discussion
4.3.1 Quartz Crystal Microbalance
Study of LipidPolyelectrolyte Multilayers
Table 4.1 summarizes the results of polyelectrolyte-lipid LbL coatings on QCM
resonators. The total thickness o f the assembled films was less than 50 nm, indicating that
the Sauerbrey Equation is valid [98].
Available data [3, 90-96], indicate that the prepared films consist of lipid bilayers
sandwiched between two polycation layers. Deposition of multiple bilayers of a
surfactant alternated with polyvinyl sulfate by the LbL method was previously reported
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[90]. The mean thicknesses for three consecutive (lipid bilayer / polyelectrolyte) layers
for different compositions are shown in Table 4.1. The thickness of a lipid
bilayer/polycation layer is in the range of 2-7 nm.
In most cases, assembly is stable when the concentration of a charged lipid in the
mixtures is 20%. The obtained (lipid bilayer/polyelectrolyte) bilayer thickness is in good
agreement with the reported values for DPPC bilayer[3, 91-96, 99, 100], The total
thickness o f a DPPC bilayer is 4.6 - 5.0 nm (including a 3.4 - 3.7 nm hydrophobic layer)
in gel state and 3.7 - 4.5 nm (2.6-3.0 nm for hydrophobic layer) in fluid state.

Table 4.1. Thickness of lipid/polyelectrolyte bilayers.
Bilayer composition8
DPPA-DPPC 5%(w/w)/PEI
DPPA-DPPC 10%(w/w)/PEI
DPPA-DPPC 17%(w/w)/PEI
DPPA-DPPC 20%(w/w)/PEI
DPPA-DPPC 5%(w/w)/PAH
DPPA-DPPC 10%(w/w)/PAH
DPPA-DPPC 17%(w/w)/PAH
DPPA-DPPC 20%(w/w)/PAH
DPPA-DPPC 5%(w/w)/PDDA
DPPA-DPPC 10%(w/w)/PDDA
DPPA-DPPC 17%(w/w)/PDD A

Freq. shift /
Hz
166 ± 51
133 ± 47
409 ± 23
284 ± 27
366 ± 39
190 ± 40
199 ± 39
161 ± 18
111 ± 10
491 ±
327 ±

10
10

PG-PC 10%(w/w)/Chitosan

273 ± 42
339 ± 65

PG-PC 20%(w/w)/Chitosan

307 ± 25

DPPA-DPPC 20%(w/w)/PDDA

Thickness'/
nm
2.65 ± 0.82
2 . 1 2 ± 0.75
6.54 ± 0.37
4.55 ± 0.43
5.86 ± 0.62
3.05 ± 0.64
3.18 ± 0.62
2.58 ± 0.29
1.78 ± 0.16
7.85 ± 1.62
5.23 ± 1.60
4.37 ± 0.67
5.42 ± 1.05
4.91 ± 0.38

a The percentages indicate total weight percent o f charged lipid components in a mixture.
bThe average o f two independent experiments.
c The frequency shift of the QCM resonators was converted into thickness using the experimental equation
A d (nm) = -0.016 A F (Hz).
_____________________

Admixture of another lipid (surfactant, hydrocarbon etc.) into a lipid bilayer can
dramatically change mean transition temperature of the mixture [ 1 0 1 ,

1 0 2

], and therefore,
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influence lipid bilayer thickness. In addition, oppositely charged substances can be
incorporated between lipid heads into hydrophilic layers slightly increasing their
thickness and decreasing hydrophobic thickness, the effect more pronounced for the
mixtures with charged lipids [103]. However, in the case of the mixtures with low
concentration of charged lipid (5-10% w/w DPP A), formation of incomplete lipid bilayer
(or polyelectrolyte layer on the top of lipid bilayer) because of absence of electrostatic
charge is possible. In the case o f strong polycation PDDA, the formation of thicker layers
can be explained by deposition of more than one DPPC-DPPS bilayer on the top of the
polycation layer to compensate its high positive charge.
The assembly of PG-PC vesicles in alternation with cationic chitosan shows a
bilayer thickness of ~5 nm. The last architecture is of considerable importance since
chitosan is a non-toxic, natural, biocompatible polymer with antimicrobial properties,
which makes this architecture suitable for in vivo applications [104].
4.3.2 Analysis of C-Potential
Measurements
For microparticles and microcapsule coatings we chose conditions giving a stable
assembly and providing a 4-5 nm thick bilayer, which is consistent with the length of two
lipid molecules [3, 90-96, 99, 105]. The lipid mixtures with 20% w/w charged lipid were
used hereafter. Lipid layers in alternation with polyelectrolytes were assembled on 3 pm
polymethacrylate microspheres (PMA) precoated with two PAH/PSS bilayers, and
changes in surface charge (^-potential) of the microparticles were measured after each
adsorption step. The detailed procedure can be found elsewhere [106]. The latex particles
were used in this series of experiments to avoid interference of lipids with multivalent
ions, which can precipitate lipids [107], The ^-potential values (Figure 4.1) show
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complete charge reversal with synthetic polyelectrolytes such as PDDA, PEI, and PAH,
and the assembly with PAH shows most consistant alternation of surface charge. For
assembly of chitosan and PG-PC, a shift in the magnitude of the positive charge was
found, but not complete charge reversal, probably because of perturbation of lipid
bilayers by chitosan [108].

80

| PDDA
A PEI
• PAH

60
•>

40

£
20

-20
-40

-60

Layer

▲ PEI
• PAH

60

>

A Chitosan

40

E
20

c

)
0
CL
1
0

-20

-40

Layer
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4.3.3 Diffusion Properties of Lipid Coated
Hollow Polvelectrolvte
Microcapsules
The possibility o f capsule coating with lipid bilayers was confirmed by deposition
o f a DPPC-17% w/w DPPA mixture with 3% admixture of l,2-dioleoyl-sn-glycero-3phosphoethanolamine-N-(carboxyfluorescein) on the top of the hollow capsules (Figure
4.2).

Figure 4.2. Lipid coating on (PAH/PSS)s to show lipid coating on
microcapsules.

The FRAP model used to study the fluorescence recovery is described in Section
2.6.3 where the two-dimensional model discussed has been used in these experiments.
Although, a three-dimensional model is recommended for volume diffusion, for diffusion
through a thin membrane, such as the microcapsule wall in our experiments a twodimensional model is a reasonable and sufficient. In the FRAP model under investigation,
the diffusion o f FITC-Dextran from the bulk to the interior of the capsule causes an
increase in fluorescence intensity in the capsule interior. The fluorescence intensity is
normalized over a given area in the interior of the capsule designated as region of interest
(ROI in Figure 2.10). The fluorescence recovery after photobleaching is in the interior of
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the hollow (PAH/PSS) 5 capsules with and without lipid coating is presented in Figure
4.3.
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Figure 4.3. Fluorescence recovery of (PSS/PAH) 5 capsules coated
with different lipid mixtures: (1) uncoated, (2) PG-PC 20% coated,
(3) DPPA-DPPC 20% coated. The intensities of capsule interior
are shown relatively that of surrounding solution.

As anticipated, the results indicate slower fluorescence recovery for lipid coated
capsules than for uncoated ones (Figure 4.3). Images in the process of photobleaching are
presented in Figure 4.4, where (Figure 4.4 A) represents the control which is uncoated
(PAH/PSS) 5 capsule, where progressively the fluorescence intensity in the interior of the
capsule increases over a period of 16 minutes. However in the lipid-coated capsules
(Figure 4.4 A and B) there is no increase in fluorescence intensity even after 75 minutes.
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Figure 4.4. Fluorescence recovery after photobleaching for
different capsules in a 10 pM solution of FITC-dextran of MW
4300: a) an uncoated (PSS/PAH) 5 capsule, b) a capsule coated
with one bilayer o f PG-PC ( 2 0 % w/w) and c) a capsule coated
with one bilayer of DPPA- DPPC (20% w/w).

The diffusion properties are a representation o f about 70% of the population.
FITC fluorescence recovery in lipid-coated capsules was slower than that in uncoated
ones indicating that the deposited lipid bilayer reduced the diffusion coefficient through
the polyelectrolyte walls drastically for low molecular substances. The diffusion
coefficient of FITC-dextran of MW 4300 into polyelectrolyte microcapsules was
evaluated on the basis o f a fluorescence recovery model proposed by Axelrod and co
workers [6 8 ], For uncoated (PSS/PAH) 5 capsules, the coefficient is (7.1±2.1)xl0 ' 12 cm2 /s.
For lipid coated capsules it is (1.4±0.3)xl0 ' 13 cm2/s (DPPA/DPPC-coated), and
(1.5±0.4)xl0 13 cm2/s (PG-PC-coated). These results indicate nearly two orders of
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magnitude difference in the diffusion coefficient for FITC-dextran of MW 4300 between
lipid-coated and uncoated microcapsules.
The diffusion coefficients for FITC-dextran with a MW 4300 estimated from this
study into uncoated and lipid coated capsules are higher than those compared with
previously reported data [2, 3, 97]. It is possible that the different core type used for
capsule preparation in this study is the cause of the higher diffusion coefficient. Previous
studies on lipid-modified capsules were based on melamine formaldehyde microparticles
and blood cells as soluble cores; however, recent evidence indicates incomplete
dissolution o f such cores, which could lead to residue in the capsules and polyelectrolyte
capsule swelling [109]. Various diffusion models used for evaluation of diffusion
coefficients can also introduce variability into results.

4.4 Conclusions
In summary, the multilayer architecture of lipid/polyelectrolyte capsules has been
reported. The lipid coating introduced directly on polyelectrolyte microcapsule surface
significantly reduces the permeability of the capsule walls. The size, wall composition,
and diffusion properties of the microcapsules are closer to biological cell wall structure
than many other model systems. These lipid/polyelectrolyte microcapsules can be a
further development o f traditional liposome delivery system technologies.
In the previous two chapters we have discussed the use of LbL assembly for
diffusion control properties that can be applied to delivery of hydrophilic drugs. In the
next chapter we will demonstrate an alternate method for delivery of hydrophobic drugs,
through entrapment of phospholipids in mineral CaCOi microparticles
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CHAPTER 5

COMPOSITE PHOSPHOLIPID - CALCIUM
CARBONATE MICROPARTICLES:
CO-ENTRAPMENT OF ANIONIC
PHOSPHOLIPIDS AND
HYDROPHOBIC
MOLECULES
5.1 Introduction
Calcium is the most abundant mineral in the human body. It is a component of
bones and teeth and is also required for blood clotting, transmission of signals in nerve
cells, and muscle contraction. The importance of calcium for preventing osteoporosis is
probably its most well-known role. Most calcium supplements contain calcium carbonate,
which is also one o f the principal components of many biomineralization schemes
occurring in nature, primarily involving a hierarchical organization of proteins and
calcium salts [110]. The control of crystal morphologies of calcium carbonate is
important for biomineralization reactions. The effect of various organic additives and
template mediated reactions on calcium carbonate crystal morphologies has been studied
[111-117]. Biomineralization in phosphatidylcholine vesicles by a diffusion-mediated
process has been reported as a model system for biomineralization [ 1 1 1 , 118].
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Most of the research has been centered on elucidating particle formation and
understanding the kinetics and mechanisms of crystallization [119-124], Recently,
Sukhrukov et al. [53] showed that porous calcium carbonate microparticles can be
synthesized by directly mixing Ca

and CO3 ' salts, which can be used as a template for

polyelectrolyte LbL assembly. Here we report the synthesis of calcium carbonate
microparticles of a highly porous nature, having phospholipid molecules entrapped in the
porous structure, resulting in an organic/inorganic complex matrix. The microparticles
can be used to load hydrophobic molecules in an inorganic core with potential
applications in medicine and industry. The calcium carbonate microparticles synthesized
in this work also show a prospect for air based nasal drug delivery systems. A surfacemediated reaction for the preparation o f the mesoporous calcium carbonate microparticles
is proposed. The resulting microparticles have phospholipids entrapped in the mineral
matrix of CaCCh with the hydrophobic material localized in the hydrophobic regions of
the phospholipids vesicles (Figure 5.1). Moreover, this scheme can be extended to the
entrapment of surface active macromolecules, including proteins, and peptide drugs.
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H y d ro p h o b ic m o le c u le s
-» e n tra p e d in th e
h y d ro p h o b ic re g io n of
th e p h s o s p h o lip id s

Drugs:
Nifidapine,
Dexamethasone

CaC03 microparticles
with phospholipids
entraped in matrix

Fluorescent Sensoric elements:
Ru(dpp) ( Oxygen sensitive dye)
fluorescent microparticles

Figure 5.1. Scheme for entrapment of hydrophobic drugs in
mineral matrix. The hydrophobic molecules are localized in the
hydrophobic tail regions of the phospholipids molecules. The
hydrophilic head interacts with the mineral matrix.

These microparticles are amenable to LbL assembly for surface modification to
make the surface o f the microparticles biocompatible; the particles can also be used as
templates for preparing hollow polyelectrolyte microcapsules by various approaches
[125]. The presence of phospholipids in the calcium carbonate matrix also facilitates
entrapment o f small hydrophobic molecules in conjugation with other bioactive
molecules.

5.2 Experimental
5.2.1 Materials.
The lipids— l,2-dipalmitoyl-sn-glycero-3-phosphate (DPPA), 1,2-distearoyl-sn-glycero3[phospho-rac-(l-glycerol)])(sodium

salt)

(DSPG),

l,2-dipalmitoyl-sn-glycero-3-

phosphatidylcholine (DPPC) and l,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N(carboxyfluorescein) (FITC-EA) were purchased from Avanti Polar Lipids. Calcium
Chloride (CaCb), and ammonium bicarbonate (NH4 HCO3 ) were purchased from Sigma
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and Fluka respectively. Tris(4,7-diphenyl-l,10-phenanthroline)ruthenium(II) dichloride
complex ([Ru (dpp^JCb) was purchased from Fluka.
5.2.2 Preparation of Calcium
Carbonate Particles
Incorporating Phospholipids
in the Matrix
To prepare calcium carbonate microparticles incorporating phospholipids in the
matrix, liposomes of DPPA (l,2-dipalmitoyl-sn-glycero-3-phosphate), DSPG (1,2distearoyl-sn-glycero-3[phospho-rac-(l-glycerol)])(sodium salt), and DPPA 20% (w/w)DPPC (1, 2- dipalmitoyl -sn-glycero-3-phosphocholine) mixtures were prepared in DI
water using standard protocol described in the previous chapter. Two mL of 1 mg/mL
phospholipid liposomes were first treated with (0.01 to 0.15 M) Ca2+ ions (CaCk) for 10
minutes with slow stirring to form cochleates [126, 127]. The cochleates were dispersed
by sonication followed by immediate addition of 0.375 M NH4HCO3 with different
volume ratios and in large excess of the stochiometric reaction requirement. After 15
minutes o f reaction, the products were centrifuged and rinsed in DI water three times
followed by rinsing in a

1:1

methanokchloroform mixture three times to remove any free

ions and phospholipids. The samples were then dried under a stream of nitrogen.
5.2.3 Preparation of Calcium
Carbonate Microparticles
Without Phospholipids in the
Matrix
Pure calcium carbonate microparticles were prepared by mixing equal volumes of
CaCb and NH4HCO3 in a constant volume reactor, at ambient conditions, with uniform
stirring. Following a 15 minute reaction, the reaction products were centrifuged, rinsed in
deionized water (DI water), and dried under a stream o f dry nitrogen.
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5.2.4 Preparation of Calcium
Carbonate Microparticles
with Hydrophobic Molecule
Entrapped in the Matirix
During the preparation of liposomes, as indicated in Section 5.2.1, the
hydrophobic molecule or fluorescent phospholipid is added to the chloroform mixture
during cake formation and the liposomes consequently formed incorporate the
hydrophobic molecules in their fatty side chains. The rest of the procedure remains the
same.

5.3 Results and Discussion
5.3.1 Characterization of
Morphology and
Microstructure
To study the morphology and microstructure of the CaCC>3 microparticles, the
samples obtained were visualized using Scanning Electron Microscopy (SEM, Gemini,
Leo 1550). The crystal structure of the CaCC>3 microparticles synthesized in the presence
and absence o f anionic phospholipids were also characterized using X-ray diffraction
•

7+

(Philips Cu xa radiation). In the absence of any additives, the reaction of Ca

3

and HCO "

yields particles with diameters in the range of 10±5 pm. The SEM images in Figure
5.2(a) and the powder X-ray diffraction pattern in Figure 5.3 indicates calcite polymorph
as the predominant form
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Figure 5.2. Representative SEM images of calcite microcrystals
prepared by reaction of 1 mL 0.01 M CaC12 + 1 mL 0.375M
NH4HC03 + 2 mL of DI water (a). Porous CaC03 microparticles
by first reacting 2 mL of 1 mg/mL DPPA +1 mL 0.01 M CaC12 +
(after 10 min) 1 mL of NH4HC03 (b), these microparticles contain
3%(w/w) phospholipids in matrix.

The shape o f the calcite crystals depends on the rate of mixing of lipids during
reaction. No-stirring results in wide size distributions of particles with fewer crystal
faces, whereas vigorous stirring yields narrower size distributions with multifaceted
particles (Figure 5.2(a)). Under identical conditions used for preparation of calcite
microparticles described above, the presence of phospholipids in the reaction-mixture
results in particles that are porous in nature and have no crystalline edges Figure 5.2(b).
The size distributions o f these microparticles are in a range of 5±2 pm.
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The powder X-ray diffraction pattern of calcium carbonate microparticles
synthesized in the presence and absence of DPPA was used to determine the polymorphs
present in the synthesized mixture. The X-ray diffraction patterns indicate that in the
absence

of phospholipids

the

resulting

calcium

carbonate

microparticles

are

predominantly calcite (Figure 5.3 (top)). In the presence of DPPA the resulting
microparticles are predominantly veterite polymorph (Figure 5.3). It is well known that
the veterite polymorph is thermodynamically less stable than calcite. The occurrence of
less stable veterite polymorph in the presence of DPPA, strongly suggests to the
involvement of phospholipids surface in altering the nucleation and crystallization of
CaCC>3 . However, traces of calcite peaks are also seen (less than 2% by volume), which
can be attributed to the phase transformation of the microparticles or some nucleation
occurring in aqueous phase as opposed to phospholipid surface.
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Figure 5.3. X-ray diffraction pattern of calcium carbonate
microparticles. The top graph shows the X-ray diffraction pattern
of calcite with the principal peaks highlighted [117]. The bottom
graph shows the X-ray diffraction pattern of calcium carbonate
microparticles synthesized in the presence of DPPA (V-veterite, Ccalcite).

5.3.2 Effect of Molar Ratio of
Reactants
The size o f the particles depends on the initial concentration of reactants. The
influence o f molar ratio of reactants on the mean size of microparticles gives an insight
into this aspect. The weighted mean of the microparticles is plotted as a function of molar
ratio o f bicarbonate and calcium (Figure 5.4) indicates a nonlinear decrease with
increasing concentration.
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Figure 5.4. Effect of the ratio of Ca2+ to HC03- ions on the size of
calcium carbonate microparticles based on 0.375 M concentration
o f NH4 HC03 in total volume, with DPPA concentration constant
at 0.2 mg/mL.

The mean diameter of the microparticles decreases with decreasing CaCl2
concentration. Higher molar ratio of CaCl2, relative to phospholipids, results in a nonhomogeneous distribution o f phospholipids in the CaCC>3 matrix that occasionally results
in rombohedral CaCC>3 calcite in the final product. This observation can also be
correlated to the fact that with lower phospholipid concentrations or non-uniform stirring
o f the reaction mixture, nucleation may begin in the aqueous phase as opposed to on the
phospholipid surface and yield a mixture of porous CaCC>3 microparticles as well as
calcite crystals.
The results indicate that a higher concentration of phospholipids to Ca2+ results in
a narrow size distribution of the resulting microparticles. In the presence of excess
phospholipids, most of the calcium ions are bound to the phospholipid surfaces, which
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results in fewer reaction centers in the media. The nucleation occurs on phospholipid
surfaces or begins in solution and propagates on the phospholipid surface resulting in a
predominantly phospholipid surface mediated reaction. To verify this hypothesis,
5%(w/w)

of

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein)

(FITC-EA) was admixed with DPPA and used to prepare the microparticles. The
resulting microparticles were visualized using a confocal laser scanning microscope
(CLSM, DMI-RE2). Figure 5.5(a) shows the confocal microscopy image of calcium
carbonate microparticles prepared in the presence of phospholipids admixed with FITCEA, which fluoresces green, and Figure 5.5(b) shows calcium carbonate microparticles
entrapped with [Ru(dpp)3 ]2+ which fluoresces red; it will be discussed in Section 5.3.5.
The distribution of fluorescence was uniform in the calcium carbonate matrices prepared
in the presence of excess phospholipids (Figure 5.5(a)) compared with microparticles
prepared in a phospholipid deficient reaction mixture (Figure 5.5(a) (inset)). The images
also illustrate that the distribution of phospholipids in the matrix is uniform and lends
support to the postulated phospholipid surface mediated reaction of calcium and
carbonate ions.
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Figure 5.5. CLSM image o f cross-section of (a) calcium carbonate
microparticles incorporating FITC-EA; in phospholipid deficient
medium the non-uniform distribution of phospholipids in the
matrix is observed (inset) and (b) prepared by reaction of CaC12
and NH4HC03 in the presence of (DPPA 20%(w/w) -DPPC
mixture containing [Ru(dpp)3]2+ which is a hydrophobic molecule
localized in the hydrophobic region of fatty acid side chain.

5.3.3 Thermogravimetric Analysis
of Calcium Carbonate
Microparticles Prepared by
Different Methods
Thermogravimetric analysis of calcium carbonate microparticles was used to
determine the temperature at which different volatile species desorb from a sample.
Figure 5.6 shows the changes in weight with temperature, the temperature of the sample
crucible was increased at the rate of 5°C per minute. The x-axis shows the changes
temperature and the y-axis is the normalized weight of the sample.
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Figure 5.6. Thermogravimetric analysis of (A) calcite and DPPA
and (B) calcium carbonate microparticles prepared in the presence
o f DPPA, the change in weight is shown as percentage total weight
(inset) (1) and mixture of calcite and DPPA (2). The temperature
was increased at 5°C/minute.

Thermogravimetric analysis of the calcium carbonate microparticles prepared in
the presence of DPPA indicated that the DPPA in the calcium carbonate matrix desorbed
at higher temperatures (385±6 °C), compared with either pure DPPA (337±6 °C) or a
physical mixture o f phospholipid with calcite microparticles (326±6 °C) (Figure 5.6). The
desorption of carbon dioxide from calcium carbonate also occurs at higher temperature
(706±6 °C) compared with pure calcite (654±6 °C) or a physical mixture of calcite and
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DPPA (681±6 °C). The higher temperature of desorption can be attributed to a strong
calcium carbonate phospholipid interaction. The microparticles contain ~ 2.5-5 % by wt.
of phospholipids in the matrix. Ca2+ ions interact with anionic phospholipids
(phosphatidic acid, phosphatidyl serine) to form a co-ordinate complex such that each
Ca2+ ion demonstrates four, and in some cases six, coordination valencies that bonds with
phosphate groups of phosphilipids or with other molecules like water [126, 127].
Lamellar amphiphile-calciumhydroxyapatite structures have been extensively studied,
which also suggest existence of such calcium ion-phospholipid coordination[65, 66,128],
The results strongly suggest that this theory could be extended to the carbonated calcium
ions in our system. Another contributing factor to the delayed desorption could be the
strong Van der Waals and hydrophobic interactions between the phospholipid vesicles
and the mesoporous matrix of the calcium carbonate. The negative-charged phospholipid
vesicle structure prevents HCO ' ion penetration into the interior of the vesicle, thus
limiting the calcification occurring only on the surface of that structure; this could lead to
nanometer sized voids explaining the porous nature of the calcium carbonate
microparticles synthesized.
5.3.4 Long-Term Stability of the
Calcium Carbonate
Microparticles
The stability of porous calcium carbonate microparticles in DI water was studied
using particles incorporating phospholipids (FITC-EA, DPPA, and DPPC mixture) with
confocal microscopy (Leica DMI RE2). Over a period of one to three weeks, the veterite
microparticles recrystallized to calcite. The first signs of recrystallization were observed
after one week of storage in an aqueous solution and progressed for 3-4 weeks, after
which nearly 90% of the microparticles had recrystallized and the phospholipids were
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excluded from the matrix. However, when the particles are dried after preparation using a
methanol:chloroform mixture, the particle morphology remains unchanged over 3-4
months.
5.3.5 Incorporation of
Hydrophobic Molecules in
Calcium Carbonate Matrix to
Simulate a Model Drug
To study the possibility to incorporate hydrophobic molecules, a model
fluorophore, tris(4,7-diphenyl-l,10-phenanthroline)ruthenium(II) dichloride complex
([Ru(dpp)3 ]Cl2 ), was incorporated in the phospholipid vesicles and the resulting
microparticles studied using CLSM (Figure 5.5(b)). [Ru(dpp)3 ]2+ is insoluble in DI water,
but readily localizes in the hydrophobic region of the phospholipid bilayer. The
distribution of the dye is uniform in the matrix of the calcium carbonate. Figure 5.5(b)
shows that the distribution o f the hydrophobic molecule [Ru(dpp)3 ]2+ is as uniform as the
distribution o f the amphiphile itself. This result is important from a pharmaceutical
standpoint, since it demonstrates the possibility that these microparticles can be used as
carriers for hydrophobic drug molecules. Preliminary trials showed feasibility to entrap
the drugs nifidapine and dexamethasone in the calcium carbonate matrix. However
further investigation is necessary to draw conclusions.

5.4 Conclusion
Anionic phospholipid (phosphatidic acid, phosphor glycerol) mediated synthesis
o f calcium carbonate microparticles from Ca2+ and HCO3' salts yields a composite
organic/inorganic matrix. The inorganic matrix is predominantly the veterite polymorph
o f calcium carbonate. The microparticles contain ~ 2.5-5 % by wt. of phospholipids in
the matrix. The phospholipids show stable entrapment in the calcium carbonate matrix
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with strong interactions with the matrix. Such architecture is conducive to the entrapment
of small hydrophobic molecules and other bioactive substances in an inorganic matrix.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER 6

CONCLUSIONS AND FUTURE WORK

6.1 Conclusions
In this dissertation the author has demonstrated that LbL self-assembly can be
applied to encapsulate peptide microparticles in the presence of high concentrations of
uncharged polymers such as PEG. Two different approaches have been used for
entrapment, which rely on the isoelectric point of the peptide. With insulin as a model
drug, with an isoelectric point ~5.9, formulations were prepared at pH 5.8 and at neutral
pH 7.0. Both pH values are relevant for pharmaceutical formulations, which are typically
prepared in the range of pH 4.0 to 8.0. Human insulin is unstable in acidic pH because of
deamidation o f the Asparagine (Asn) residue located at A21, leading to long term storage
instability. However, acidic pH insulin formulations dissociate at a faster rate compared
with neutral pH formulations. At pH 5.8 the insulin microparticles behave like a positive
core and LbL assembly was achieved using a polyanion as the first layer. The LbL thin
films form complex with the outermost layer of insulin molecules, imparting some degree
o f structural integrity to the microparticle in storage. Available literature [8] strongly
suggests that the structural integrity prevents the release of insulin in storage at pH 5.8,
thus limiting the adverse effects of dilution of insulin. The adverse effects which could
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induce loss of therapeutic value of insulin include— polymerization, chemical
modification, adsorption to storage vessel wall, fibril growth and crystallization. At pH
7.0 PROMAXX® insulin microparticles behave as a negative core and the LbL assembly
was performed using a polycation as the first layer. It was observed that differential
number of layers enables differential control of drug. This effect was most pronounced in
ProtS/CMC combination. This is interesting from the point that the adsorbed layers are
nanometers thick and the influence of a single outermost layer can be significant.
However, there is significant penetration of polyelectrolyte inside the insulin core, thus
forming stable complex in storage. This complex formation imparts similar benefits as
stated above for pH 5.8.
The study involving complex formation established the amount of polyelectrolyte
required for complete complex formation. This information is useful for process scaleup
and can be efficiently employed on a larger scale to avoid the rinsing steps that were
performed in the experiments described in this work. The absence of rinsing would
consequently lead to a reduction in the amount of materials used, providing significant
cost benefits. Further, this information alone can be used to create formulations with
release properties entirely regulated by the amount of polyelectrolyte added. The
experimental results relating different polyelectrolytes and corresponding release kinetics
can be used as a library for polyelectrolyte-insulin complex reversibility, thus aiding
better material selection in the future. Such a library also provides information for better
understanding insulin-polyelectrolyte complexes and designing a mathematical model for
a specific material, which in turn would lead to the development of an in vivo model. The
work presented in Chapter 3 leads us to a general idea which applies to all LbL
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assemblies on protein cores, in that when a negatively charged protein interacts
alternatively with a cationic and anionic polyelectrolyte, the relative affinity of the inter
polyelectrolyte interaction may dictate the overall strength of protein-polyelectrolyte(s)
complex. Converse is true for a positively charged protein core.
The insulin coating with LbL was performed mostly with the use of biologically
derived polyelectrolytes, with occasional use of synthetic polyelectrolytes to relate with
existing knowledge on LbL. Consequently, the experiments were designed to identify the
polyelectrolytes which yielded the desired results, and investigate them further. It was
demonstrated that different polyelectrolytes can be used as the outermost coating, thus
imparting desired surface charge at any pH value. This work also suggests that the use of
pegylated polyelectrolytes as the outermost layer of the LbL assembly on insulin
microparticles results in a PEG-terminated outer coating, which has been known to be
completely biocompatible.
The use o f phospholipids in LbL assembly was treated as a separate chapter,
because establishing proof of concept was essential prior to use in drug formulation.
Phospholipids were used because they are inherently biocompatible in nature and are
used in existing drug formulations. However, the work presented in this dissertation
established the right concentration of charged anionic and zwitterionic lipids for use in
LbL. Further, as an extension o f work by Moya et al.[3], who demonstrated the feasibility
to make a single lipid bilayer structure, this work presents the prospect of using
multilayer lipid-polyelectrolyte constructs. Differing from earlier works, which enable
the coating of solid colloidal particles, this work establishes the coating on hollow
polyelectrolyte multilayer capsules. Moreover, the author has provided the first of its kind
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comparison of diffusion properties of hollow polyelectrolyte capsules and lipid coated
polyelectrolyte capsules. Conventional LbL assembly does not use phospholipids as a
component of the thin films, and relies primarily on the number of layers of
polyelectrolyte to regulate the diffusion of substances from microcapsules. Increasing
number of layers incurs a great deal of time and materials cost. The use of phospholipids
could significantly reduce these, and the work presented in this dissertation is a
significant achievement in terms of establishing the usefulness of lipid polyelectrolyte
multilayers. The choice of FITC-Dextran MW4300 is guided by its molecular weight,
which is close to the molecular weight of insulin. The use of a diffusion technique used to
load hollow polyelectrolyte shells could potentially be used to load hollow
polyelectrolyte multilayer capsules, followed by outermost lipid coating could be used to
design a slow-release formulation. Alternatively, the use of insulin cores or crystals
coated with LbL multilayers followed by an outermost lipid coat can also be envisaged.
The size, wall composition, and diffusion properties of the lipid/polyelectrolyte
microcapsules developed in this work are closer to biological cell wall structure than
many other model systems. These lipid/polyelectrolyte microcapsules can be treated as a
further development of traditional liposome delivery system technologies. This work
could be beneficially exploited by reinforcing liposomal technology with the use of
electrostatic layer-by-layer technology, thus enhancing the existing liposomal technology
for drug delivery.
Extending the particulate delivery technology the incorporation of hydrophobic
and surface active molecules in an inorganic core is a new dimension in drug delivery.
The novelty of the method lies in the use of anionic phospholipids (phosphatidic acid,
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phosphoglycerol)-mediated synthesis of calcium carbonate microparticles from Ca2+ and
HCO3' salts yields a composite organic/inorganic matrix. The inorganic matrix is
predominantly the veterite polymorph of calcium carbonate. The microparticles contain ~
2.5-5 % by wt of phospholipids in the matrix. The phospholipids show stable entrapment
in the calcium carbonate matrix and strong interactions with the matrix. Such architecture
is conducive to the entrapment of small hydrophobic molecules and other bioactive
substances in an inorganic matrix. Surprisingly, a large number of macromolecules are
surface active in that they show a tendency to selectively partition at an interface. The
development o f calcium carbonate microparticles entrapping phospholipids is based on
the surface active properties of phospholipids. It can be inferred that, this technique of
entrapping material can be extended to insulin, and similar peptide drugs which are
amphoteric in nature. Further phospholipids can be used advantageously to boost the drug
loading in the calcium carbonate matrix because existing literature on material loading
into calcium carbonate microparticles suggests a loading o f less than 1% in most cases.

6.2 Future work
The insulin reformulation with LbL was designed with biocompatible,
biodegradeable polymers. The choice of materials was guided by its biological source,
and inherent capacity o f biological organisms to degrade the materials, or the presence of
pathways for removal of the material. Although the word biocompatibility is used
liberally to describe a whole set of biologically derived polymers, in vivo testing is
essential in establishing the true behavior of the material for a given mammalian species.
Further, the viability o f the drug depends on its bioavailability and release kinetics in
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vivo. Hence, animal models need to be developed for nasal drug delivery of the prepared
formulations.
As a further development the use of phospholipids in LbL scheme can be applied
to insulin cores, which is proving a problem under the conditions used for preparation of
LbL thin films on PROMAXX® insulin microparticles. This work used PEG buffer for
preparation of the insulin drug formulation, the buffer also contains trace quanties of Zn
ions, both PEG and zinc cause problems with phospholipid vesicle stability. Moreover
the work presented in this dissertation involved the use of DI water for preparation of
phospholipid-polyelectrolyte multilayer films adding a constraint to the use of the
technique. An investigation on the suitability of other amphiphilic molecules may be
required.
The calcium carbonate microparticles show good prospect for loading
hydrophobic and surface active drugs. Testing the efficacy of the platform for drugs and a
study o f the rehology o f the particles for air based delivery systems would be crucial for
the development of the platform.
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